UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

 

FORM 10-Q

 

QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934

 

For the quarterly period ended March 31, 2025

 

TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934

 

For the transition period from ___________ to ___________

 

Commission file number 001-40903

 

HEALTHCARE TRIANGLE, INC.

(Exact name of registrant as specified in its charter)

 

Delaware   84-3559776
(State or other jurisdiction of
incorporation or organization)
  (I.R.S. Employer
Identification No.)
     
7901 Stoneridge Drive, Suite 220 Pleasanton, CA   94588
(Address of principal executive officer)   (Zip Code)
     
(925) 270-4812
(Registrant’s telephone number, including area code)

 

Title of each class   Ticker Symbol(s)   Name of each exchange on which registered
Common Stock, $0.00001 par value   HCTI   The Nasdaq Stock Market LLC

 

Indicate by check mark whether the registrant (1) has filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that the registrant was required to file such reports), and (2) has been subject to such filing requirements for the past 90 days.

 

Yes  No

 

Indicate by check mark whether the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T (§ 232.405 of this chapter) during the preceding 12 months (or for such shorter period that the registrant was required to submit such files).

 

Yes  No

 

Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, or a smaller reporting company. See the definitions of “large accelerated filer”, “accelerated filer”, “smaller reporting company”, and “emerging growth company” in Rule 12b-2 of the Exchange Act.

 

Large accelerated filer Accelerated filer Non-accelerated filer Smaller reporting company Emerging growth company

 

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act.

 

Indicate by check mark whether the registrant is a shell company (as defined in Rule 12b-2 of the Act).

 

Yes  No

 

As of May 19, 2025, 408,445,597 shares of the registrant’s common stock, $0.00001 par value per share, were issued and outstanding.

 

 

 

 

 

Table of Contents

 

Note About Forward-Looking Statements   ii
PART I – FINANCIAL INFORMATION   1
Item 1. Financial statements   1
Unaudited Condensed Consolidated Balance sheets   1
Unaudited Condensed Consolidated Statements of Operations     2
Unaudited Condensed Consolidated Statements of Changes in Stockholders’ Equity (Deficit)   3
Unaudited Condensed Consolidated Statements of Cash Flows   4
Notes to Unaudited Condensed Consolidated Financial Statements   5
Item 2. Management’s Discussion and Analysis of Financial Condition and Results of Operations   27
Item 3. Quantitative and Qualitative Disclosures About Market Risk   38
Item 4. Controls and Procedures   38
PART II - OTHER INFORMATION   39
Item 1. Legal Proceedings   39
Item 1A. Risk Factors   39
Item 2. Unregistered Sales of Equity Securities and Use of Proceeds   39
Item 3. Defaults Upon Senior Securities   39
Item 4. Mine Safety Disclosures   39
Item 5. Other Information   39
Item 6. Exhibits   40
Signatures   41

 

i

 

NOTE ABOUT FORWARD-LOOKING STATEMENTS

 

This Quarterly Report on Form 10-Q, including the sections titled “Management’s Discussion and Analysis of Financial Condition and Results of Operations” and “Risk Factors,” contains certain forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended, involving substantial risks and uncertainties. The words “believe,” “may,” “will,” “potentially,” “plan,” “could,” “should,” “predict,” “ongoing,” “estimate,” “continue,” “anticipate,” “intend,” “project,” “expect,” “seek,” or the negative of these words, or terms or similar expressions conveying uncertainty of future events or outcomes, or that concern our expectations, strategy, plans or intentions, are intended to identify forward-looking statements. Forward-looking statements involve risks and uncertainties that could cause actual results to differ materially from those projected, anticipated, or expected. When considering forward-looking statements, you should keep in mind the risk factors and other cautionary statements discussed under the heading “Risk Factors” and in our publicly available filings and press releases. These statements include, among other things, those regarding:

 

  our ability to continue to add new customers and increase sales to our existing customers;

 

  our ability to develop new solutions and bring them to market in a timely manner;

 

  our ability to timely and effectively scale and adapt our existing solutions;

 

  our dependence on establishing and maintaining a strong brand;

 

  the occurrence of service interruptions and security or privacy breaches and related remediation efforts and fines;

 

  system failures or capacity constraints;

 

  the rate of growth of, and anticipated trends and challenges in, our business and in the market for our products;

 

  our future financial performance, including our expectations regarding our revenue, cost of revenue, operating expenses, including changes in technology and development, marketing and advertising, general and administrative and customer care expenses, and our ability to achieve and maintain future profitability;

 

  our ability to continue to efficiently acquire customers, maintain our high customer retention rates and maintain the level of our customers’ lifetime spend;

 

  our ability to provide high quality customer care;

 

  the effects of increased competition in our markets and our ability to compete effectively;

 

  our ability to grow internationally;

 

  the impact of fluctuations in foreign currency exchange rates on our business and our ability to effectively manage the exposure to such fluctuations;

 

  our ability to effectively manage our growth and associated investments, including our migration of the vast majority of our infrastructure to the public cloud;

 

  our ability to maintain our relationships with our partners;

 

  adverse consequences of our substantial level of indebtedness and our ability to repay our debt;

 

  our ability to maintain, protect and enhance our intellectual property;

 

  our ability to maintain or improve our market share;

 

  sufficiency of cash and cash equivalents to meet our needs for at least the next 12 months;

 

ii

 

  beliefs and objectives for future operations;

 

  our ability to stay in compliance with laws and regulations currently applicable to, or which may become applicable to, our business both in the United States (U.S.) and internationally;

 

  economic and industry trends or trend analysis;

 

  our ability to attract and retain qualified employees and key personnel;

 

  anticipated income tax rates, tax estimates and tax standards;

 

  interest rate changes;

 

  the future trading prices of our common stock;

 

  our expectations regarding the outcome of any regulatory investigation or litigation;

 

  the amount and timing of future repurchases of our common stock under any share repurchase program;

 

  the potential impact of shareholder activism on our business and operations;

 

  the length and severity of the coronavirus (COVID-19) pandemic and its impact on our business, customers and employees; as well as other statements regarding our future operations, financial condition, growth prospects and business strategies.

 

We operate in very competitive and rapidly-changing environments, and new risks emerge from time-to-time. It is not possible for us to predict all risks, nor can we assess the impact of all factors on our business or the extent to which any factor, or combination of factors, may cause actual results to differ materially from those contained in any forward-looking statements we may make. In light of these risks, uncertainties and assumptions, the forward-looking events discussed in this report may not occur, and actual results could differ materially and adversely from those implied in our forward-looking statements.

 

You should not rely upon forward-looking statements as predictions of future events. Although we believe the expectations reflected in our forward looking statements are reasonable, we cannot guarantee the future results, levels of activity, performance or events and circumstances described in the forward looking statements will be achieved or occur. Neither we, nor any other person, assume responsibility for the accuracy and completeness of the forward looking statements. We undertake no obligation to publicly update any forward-looking statements for any reason after the date of this report to confirm such statements to actual results or to changes in our expectations, except as required by law. Given these risks and uncertainties, readers are cautioned not to place undue reliance on such forward-looking statements.

 

Unless expressly indicated or the context suggests otherwise, references to “Healthcare Triangle,” “company,” “we,” “us” and “our” refer to Healthcare Triangle Inc. and its consolidated subsidiary.

 

iii

 

PART I

 

FINANCIAL INFORMATION

 

Item 1. Financial statements (In thousands of US $, unless otherwise noted)

 

HEALTHCARE TRIANGLE, INC.

Condensed Consolidated Balance Sheets

 

    March 31,     December 31,  
    2025     2024  
    (Unaudited)        
Assets            
Current assets            
Cash and cash equivalents   $ 6,826     $ 20  
Accounts receivable     1,907       1,110  
Other current assets     1,107       322  
Total current assets     9,840       1,452  
Property and equipment, net     -       12  
Due from affiliates     1,945       497  
Total assets   $ 11,785     $ 1,961  
                 
Liabilities and stockholders’ equity (deficit)                
Current liabilities                
Accounts payable   $ 1,618     $ 2,539  
Short term borrowing     775       2,650  
Other current liabilities     815       1,386  
Total current liabilities     3,208       6,575  
                 
Long-term liabilities                
Contingent consideration     -       500  
Total current and long-term liabilities     3,208       7,075  
                 
Stockholders’ equity                
Preferred stock, par value $0.00001; 10,000,000 authorized Issued 1,600,000 as of March 31, 2025 and as of December 31, 2024     7,435       7,435  
Series A, Super Voting Preferred Stock - 20,000 shares (1,000 votes per share)     -       -  
Common stock, par value $0.00001; 100,000,000 authorized 16,038,376 and 5,666,781 shares issued and outstanding as of March 31, 2025, and December 31, 2024 respectively     -       -  
Additional paid-in capital     36,413       21,022  
Accumulated deficit     (35,271 )     (33,571 )
Total stockholders’ equity (deficit)     8,577       (5,114 )
Total liabilities and stockholders’ equity   $ 11,785     $ 1,961  

  

The accompanying notes are an integral part of these unaudited condensed consolidated financial statements.

 

1

 

HEALTHCARE TRIANGLE, INC.

 

Unaudited Condensed Consolidated Statements of Operations

 

   Three Months Ended
March 31,
 
   2025   2024 
         
Net revenue  $3,704   $4,109 
           
Cost of revenue (exclusive of depreciation and amortization shown separately below)   3,375    3,095 
           
Operating expenses          
Research and development   144    127 
Sales and marketing   373    883 
General and administrative   1,198    1,181 
Depreciation and amortization   12    536 
Total operating expenses   1,727    2,727 
Loss from operations   (1,398)   (1,713)
Other income   111    
-
 
Interest expense   (413)   (149)
Loss before income tax   (1,700)   (1,862)
Provision for income   tax   
-
    
-
 
Net loss  $(1,700)  $(1,862)
Net loss per common share—basic and diluted   (0.17)   (0.42)
Weighted average shares outstanding:          
Basic and diluted   9,843,821    4,455,245 

  

The accompanying notes are an integral part of these unaudited consolidated financial statements.

 

2

 

HEALTHCARE TRIANGLE, INC.

 

Unaudited Consolidated Statements of Changes in Stockholder’s Equity

 

   Preferred stock (Series A)   Preferred stock (Series B)   Common stock   Additional
paid-in
   Accumulated   Total stockholders' 
   Shares   Amount   Shares   Amount   Shares   Amount   capital   defecit   equity (deficit) 
Three months ended March 31, 2025                                    
Balance at December 31, 2024   6,000   $
             -
    1,600,000   $7,435    5,666,781    
        -
   $21,022   $(33,571)  $(5,114)
Net loss   -    -    -    -    -    -    -    (1,700)   (1,700)
Shares issued for services   14,000    
-
    
-
    
-
    130,977    
-
    88    
-
    88 
Common Stock issued for cash   -    
-
    -    
-
    7,017,429    
-
    95    
-
    95 
Prefunded warrants issued for cash (1)     
-
    
-
    
-
    
-
    
-
    
-
    395    
-
    395 
Series B (cashless warrants) (2)   
-
    
-
    
-
    
-
    
-
    
-
    14,710    
-
    14,710 
Expenses relating to funding   -    
-
    -    
-
    -    
-
    (1,524)   
-
    (1,524)
Conversion of Debt to Equity   -    
-
    -    
-
    2,629,040    
-
    1,191    
-
    1,191 
Shares issued for acquisition (Contingent Consideration)        
 
         
 
    594,129    
-
    400    
-
    400 
Issue of Options (ISO/NSO)   -    
-
    -    
-
    -    
-
    36    
-
    36 
Balance at March 31, 2025   20,000   $
-
    1,600,000   $7,435    16,038,376    
-
   $36,413   $(35,271)  $8,577 
                                              
Three months ended March 31, 2024                                             
Balance at December 31, 2023   6,000   $
-
    
-
   $
-
    4,308,822    
-
   $26,211   $(27,602)  $(1,392)
Net loss                                      (1,862)   (1,862)
Preferential Issue   -    
-
    -    
-
    417,395    
-
    787    
-
    787 
Issue of Options (ISO/NSO)   -    
-
    -    
-
    -    
-
    26    
-
    26 
Balance at December 31, 2024   6,000   $
-
    
-
   $
-
    4,726,217    
-
   $27,024   $(29,464)  $(2,441)

 

The accompanying notes are an integral part of these unaudited condensed consolidated financial statements.

 

(1)29,173,056 shares of Common Stock that may be issued on full exercise of the pre-funded warrants issued at $0.42 per share.

 

(2)Up to 1,085,714,550 shares of Common Stock that may be issued on exercise of the Series B warrants using the “zero exercise price option”.

 

See Note 8 for value allocation.

 

3

 

HEALTHCARE TRIANGLE, INC.

 

Unaudited Condensed Consolidated Statements of Cash Flows

 

   Three Months Ended
March 31,
 
   2025   2024 
Cash flows from operating activities        
Net loss  $(1,700)  $(1,862)
Adjustment to reconcile net income (loss) to net cash provided by (used in) operating activities          
Depreciation & amortization   12    536 
Interest expense settled by equity   316    
-
 
Common stock issued for services   88    
-
 
Amortization of debt discount   223    36 
Other income   (111)   
-
 
Stock compensation expenses   36    26 
Changes in operating assets and liabilities:        
(Increase)/ decrease in:          
Accounts receivable   (797)   1,141 
Other current assets   (785)   486 
Due from affiliates   (1,448)   271 
Accounts payable and accrued expenses   (820)   60 
Other current liabilities   (572)   (744)
Net cash used in operating activities   (5,557)   (50)
Cash flows from investing activities          
Net cash provided by/ (used in) investing activities   
-
    
-
 
Cash flows from financing activities          
Increase/(decrease) in short term borrowing   186    (883)
Repayment of convertible note   (1,500)   
-
 
Proceeds from equity issuance (Note 8)   13,677    
-
 
Net cash provided by/ (used in) financing activities   12,363    (883)
           
Net increase (decrease) in cash and cash equivalents   6,806    (933)
Cash and cash equivalents          
Cash and cash equivalents at the beginning of the period  $20   $1,234 
Cash and cash equivalents at the end of the period  $6,826   $301 
           
Non-cash investing and financing activities          
           
Supplementary disclosure of cash flows information          
Interest   413    149 
Conversion of debt to equity   

1,191

    

-

 

  

The accompanying notes are an integral part of these condensed consolidated financial statements.

 

4

 

HEALTHCARE TRIANGLE, INC.

 Notes To Condensed Consolidated Financial Statements

(Unaudited)

(In thousands except share and per share data)

 

1) Organization and Description of Business

 

Healthcare Triangle Inc. (“the Company”) was incorporated under the laws of the State of Nevada on October 29, 2019, and then converted into a Delaware corporation on April 24, 2020, to provide IT and data services to the Healthcare and Life Sciences (‘HCLS”) industry. On January 1, 2020, the Company acquired the Life Sciences Business of SecureKloud Technologies Inc. (“Parent”) and on May 8, 2020, the Company acquired Cornerstone Advisors Group LLC (Healthcare Business) from its Parent.

 

Company reinforces healthcare progress through breakthrough technology and extensive industry know-how. Company support healthcare providers and payors, hospitals and pharma/life sciences organizations in their effort to improve health outcomes by enabling the adoption of new technologies, data enlightenment, business agility and accelerate responding to immediate business needs and competitive threats. The highly regulated HCLS industry turn to Company for expertise in digital transformation on the cloud, security and compliance, develops, data lifecycle management, healthcare interoperability, clinical and business performance optimization. 

 

Company concentrates on accelerating value to the three healthcare sectors:

 

 

 

1. Pharmaceutical companies, which require improved efficiencies in the clinical trial process. Company modernizes their IT infrastructure to advance the clinical trial process to drug discovery and delivery.

 

  2. Hospitals and health systems, which face interoperability challenges as mergers, acquisitions and partnerships drive increasing need for integrated healthcare infrastructures. Company’s health IT expertise optimizes providers’ enterprise digital structure needs connecting disparate systems and applying analytics capabilities.

 

  3. Life sciences, payers and all healthcare organizations must protect and secure personal health information (PHI), a regulatory compliance mandate that Company addresses and manages for its customers.

 

As an organization with the deep-rooted cloud expertise, Company’s technology significantly relies on Big Data, Analytics, DevOps, Security/Compliance, Identity Access Management (IAM), Machine Learning (ML), Artificial Intelligence (AI), Internet of Things (IoT) and Blockchain.

 

5

 

HEALTHCARE TRIANGLE, INC.

Notes To Condensed Consolidated Financial Statements

(Unaudited)

(In thousands except share and per share data)

 

2) Summary of Significant Accounting Policies

 

Basis of consolidated financial statements

 

The accompanying condensed consolidated financial statements include the accounts of Healthcare Triangle, Inc and Devcool, Inc its wholly owned subsidiary. The condensed consolidated financial statements have been prepared in accordance with accounting principles generally accepted in the United States of America. All intercompany balances and transactions have been eliminated in consolidation.

 

The accompanying statements of operations include expenses for certain functions historically performed by the Parent company, including general corporate services, such as legal, accounting, treasury, information technology, human resources and administration. These expenses are based primarily on direct usage when identifiable, direct capital expenditures or other relevant allocations during the respective periods. We believe the assumptions underlying the accompanying condensed consolidated financial statements, are reasonable. Actual results may differ from these expenses, assumptions and estimates. The amounts recorded in the accompanying condensed consolidated financial statements are not necessarily indicative of the actual amount of such indirect expenses that would have been recorded had we been a separate independent entity.

 

Unaudited Interim Financial Information

 

The accompanying unaudited condensed consolidated financial statements and the related footnote disclosures have been prepared by us in accordance with GAAP for interim financial reporting and as required by Rule 10-01 of Regulation S-X. Accordingly, the unaudited condensed consolidated financial statements may not include all of the information and notes required by GAAP for audited financial statements. The year-end December 31, 2024 condensed consolidated balance sheet data included herein was derived from audited financial statements. In the opinion of management, the accompanying unaudited condensed consolidated financial statements contain all adjustments, consisting of items of a normal and recurring nature, necessary to present fairly our financial position as of March 31, 2025, the results of operations, comprehensive income (loss), stockholders’ deficit, and cash flows for the three months ended March 31, 2025 and 2024. The results of operations for the three months ended March 31, 2025 and 2024 are not necessarily indicative of the results to be expected for the full year. The information contained herein should be read in conjunction with the unaudited financial statements included in our Annual Report on Form 10-K for the year ended December 31, 2024 filed with the SEC. Management considers events or transactions that occur after the balance sheet date but before the financial statements are issued to provide additional evidence relative to certain estimates or to identify matters that require additional disclosure. Subsequent events have been evaluated through the date of issuance of these financial statements.

 

6

 

HEALTHCARE TRIANGLE, INC.

Notes To Condensed Consolidated Financial Statements

(Unaudited)

(In thousands except share and per share data)

 

Accounting Policies

 

Use of Estimates

 

The preparation of financial statements is in conformity with GAAP which requires us to make estimates, judgments and assumptions that affect the financial statements and the notes thereto. These estimates are based on information available as of the date of the financial statements. On a regular basis, management evaluates these estimates and assumptions. Items subject to such estimates and assumptions include, but are not limited to:

 

  the standalone selling price for each distinct performance obligation

 

  the determination of the period of benefit for amortization of deferred costs.

 

  the fair value of assets acquired, and liabilities assumed for business combinations.

 

  Share based compensation including warrants

 

Emerging Growth Company Status

 

We are an “emerging growth company,” as defined in the Jumpstart Our Business Startups Act of 2012. We will remain an emerging growth company until the earlier of (i) December 21, 2026 (the last day of the fiscal year following the fifth anniversary of our IPO), (ii) the last day of the first fiscal year in which we have total annual gross revenue of at least $1.07 billion, (iii) the last day of the first fiscal year in which we are deemed to be a “large accelerated filer”, as defined in the rules under the Exchange Act, and (iv) the date on which we have issued more than $1.0 billion in non-convertible debt during the prior three-year period. We refer to the Jumpstart Our Business Startups Act of 2012 herein as the “JOBS Act,” and any reference herein to “emerging growth company” has the meaning ascribed to it in the JOBS Act.

 

We have elected to take advantage of certain of the reduced disclosure obligations in this Annual Report on Form 10-K and may elect to take advantage of other reduced reporting requirements in our future filings with the SEC. As a result, the information that we provide to our stockholders may be different from the information you might receive from other public reporting companies in which you hold equity interests. In particular, Section 107 of the JOBS Act provides that an emerging growth company can take advantage of the extended transition period provided in Section 7(a)(2)(B) of the Securities Act of 1933, as amended (the Securities Act) for complying with new or revised accounting standards. Thus, an emerging growth company can delay the adoption of certain accounting standards until those standards would otherwise apply to private companies. We have elected to avail ourselves of this extended transition period and, as a result, so long as we remain an emerging growth company, we will not be subject to the same implementation timing of new or revised accounting standards as other public companies that are not emerging growth companies until these standards apply to private companies unless we elect to early adopt as permitted by the relevant guidance for private companies.

 

Segment Information

 

The management has chosen to organize the Company around differences in products and services and segregated the reporting segments as Software Services, Managed Services and Support, and Platform Services.

 

Operating segments are defined as components of an enterprise about which separate financial information is evaluated regularly by the chief operating decision maker in deciding how to allocate resources and assessing performance. The Company defines the term ‘chief operating decision maker’ to be the Chief Financial Officer and Chief Operating Officer. The Chief Financial Officer along with the management team reviews the financial information presented on a consolidated basis for purposes of allocating resources and evaluating our financial performance. Accordingly, the Company has determined that it operates in three distinct reportable operating segments, and all required financial segments information can be found in the condensed consolidated financial statements.

 

7

 

HEALTHCARE TRIANGLE, INC.

Notes To Condensed Consolidated Financial Statements

(Unaudited)

(In thousands except share and per share data)

 

Expenses included in segment operating profit consist principally of direct selling, delivery costs and research and development expenses. Certain Sales and Marketing expenses, General and Administrative expenses, depreciation, and amortization are not allocated to individual segments in internal management reports used by the chief operating decision maker. Accordingly, such expenses are excluded from segment operating profit and are included below as “unallocated costs” and adjusted against our total income from operations. Additionally, management has determined that it is not practical to allocate identifiable assets by segment, since such assets are used interchangeably among the segments.

 

Schedule of operating segment

 

   Three months Ended
March 31,
   Changes 
   (In thousands)     
   2025   2024   Amount   % 
Software services  $1,652    2,025    (373)   (18)%
Managed services and support   1,982    1,996    (14)   (1)%
Platform services   70    88    (18)   (20)%
Revenue  $3,704   $4,109   $(405)   (10)%

 

Operating profit by Operating Segment

 

Three months ended March 31, 2025
Particulars  Software
Services
   Managed
Services
   Platform
Services
   Total 
Revenue from customers   1,734    1,900    70    3,704 
Intersegment revenues   
-
    
-
    
-
    
-
 
Total   1,734    1,900    70    3,704 
Less:                    
Elimination of intersegment revenues   
-
    
-
    
-
    
-
 
Cost of revenue   (1,543)   (1,823)   (9)   (3,375)
Segmental gross profit   191    77    61    329 
Research and development   
-
    
-
    144    144 
Sales and marketing   175    191    7    373 
General and administrative   561    615    23    1,198 
Segmental loss   (544)   (729)   (113)   (1,386)
Interest expenses   (193)   (212)   (8)   (413)
Depreciation and amortization   
-
    
-
    (12)   (12)
Other income   52    57    2    111 
Income before income taxes   (686)   (884)   (130)   (1,700)
Income tax   -    -    -    - 
Income after income taxes   (686)   (884)   (130)   (1,700)

 

8

 

HEALTHCARE TRIANGLE, INC.

Notes To Condensed Consolidated Financial Statements

(Unaudited)

(In thousands except share and per share data)

 

Three months ended March 31, 2024
Particulars  Software
Services
   Managed
Services
   Platform
Services
   Total 
Revenue from customers   2,025    1,996    88    4,109 
Intersegment revenues   -    -    -    - 
Total   2,025    1,996    88    4,109 
Less:                  - 
Elimination of intersegment revenues   -    -    -    - 
Cost of revenue   (1,625)   (1,414)   (56)   (3,095)
Segmental gross profit   400    582    32    1,014 
Research and development   -    -    127    127 
Sales and marketing   435    429    19    883 
General and administrative   582    574    25    1,181 
Segmental profit / (loss)   (617)   (421)   (139)   (1,177)
Interest expenses   (73)   (72)   (3)   (149)
Depreciation   -    -    (536)   (536)
Amortization   -    -    -    - 
Other income   -    -    -    - 
Income before income taxes   (691)   (493)   (678)   (1,862)
Income tax   -    -     -    - 
Income after income taxes   (691)   (493)   (678)   (1,862)

 

 

Revenue from top 5 customers

 

Three Months Ended March 31, 2025

 

Schedule of concentration

 

Customer  Amount
(In thousands)
   % of
Revenue
 
Customer 1  $        754    20%
Customer 2   659    18%
Customer 3   266    7%
Customer 4   233    6%
Customer 5  $188    5%

 

Three Months Ended March 31, 2024

 

Schedule of concentration

 

Customer   Amount
(In thousands)
    % of
Revenue
 
Customer 1   $         807       20 %
Customer 2     720       18 %
Customer 3     490       12 %
Customer 4     476       12 %
Customer 5   $ 332       8 %

 

9

 

HEALTHCARE TRIANGLE, INC.

Notes To Condensed Consolidated Financial Statements

(Unaudited)

(In thousands except share and per share data)

 

Revenue Recognition

 

We recognize revenues as we transfer control of deliverables (services, solutions, and platform) to our clients in an amount reflecting the consideration to which we expect to be entitled. To recognize revenues, we apply the following five step approach: (1) identify the contract with a customer, (2) identify the performance obligations in the contract, (3) determine the transaction price, (4) allocate the transaction price to the performance obligations in the contract, and (5) recognize revenues when a performance obligation is satisfied. We account for a contract when it has approval and commitment from all parties, the rights of the parties are identified, payment terms are identified, the contract has commercial substance and collectability of consideration is probable. We apply judgment in determining the customer’s ability and intention to pay based on a variety of factors including the customer’s historical payment experience.

 

For performance obligations where control is transferred over time, revenues are recognized based on the extent of progress towards completion of the performance obligation. The selection of the method to measure progress towards completion requires judgment and is based on the nature of the deliverables to be provided.

 

Software Services

 

The Company enters into contractual obligations with the customers to perform (i) Strategic advisory services which include assessment of the enterprise network, applications environment and advise on the design and tools; (ii) Implementation services which include deployment, upgrades, enhancements, migration, training, documentation and maintenance of various electronic health record systems and (iii) Development services which include customization of network and applications in the public cloud environment.

 

Revenue from Strategic advisory, Implementation and Development services are distinct performance obligation and is recognized on time-and-material or fixed-price project basis. Revenues related to time-and-material are recognized over the period the services are provided using labor hours. Revenues related to fixed-price contracts are recognized as the service is performed using the cost-to-cost method, under which the total value of revenues is recognized based on the percentage that each contract’s total labor cost to date bears to the total expected labor costs. The cost-to-cost method requires estimation of future costs, which is updated as the project progresses to reflect the latest available information; such estimates and changes in estimates involve the use of judgment. The cumulative impact of any revision in estimates is reflected in the financial reporting period in which the change in estimate becomes known and any anticipated losses on contracts are recognized immediately, where appropriate.

 

We may enter into contracts that consist of multiple performance obligations. Such contracts may include any combination of our deliverables. To the extent a contract includes multiple promised deliverables, we apply judgment to determine whether promised deliverables are capable of being distinct and are distinct in the context of the contract. If these criteria are not met, the promised deliverables are accounted for as a combined performance obligation. For contracts with multiple distinct performance obligations, we allocate consideration among the performance obligations based on their relative standalone selling price. Standalone selling price is the price at which we would sell a promised good or service separately to the customer. When not directly observable, we estimate standalone selling price by using the expected cost plus a margin approach. We establish a standalone selling price range for our deliverables, which is reassessed on a periodic basis or when facts and circumstances change.

 

10

 

HEALTHCARE TRIANGLE, INC.

Notes To Condensed Consolidated Financial Statements

(Unaudited)

(In thousands except share and per share data)

 

Managed Services and Support

 

The Company has standard contracts for its Managed Services and Support, however the statement of work contained in such contracts is unique for each customer. A typical Managed Services and Support contract would provide for some or all of the following types of services being provided to the customer: Cloud hosting, Continuous monitoring of applications, security and compliance and support.

 

Revenue from Managed services and support is a distinct performance obligation and recognized based on SSP (standalone selling price), ratably on a straight-line basis over the period in which the services are rendered. Contract with customers includes subcontractor services or third-party cloud infrastructure services in certain integrated services arrangements. In these types of arrangements, revenue is recognized net of costs when the Company is acting as an agent between the customer and the vendor, and gross when the Company is the principal for the transaction. In doing so, the Company first evaluates whether it controls the platform or service before it is transferred to the customer. The Company considers whether it has the primary obligation to fulfil the contract, pricing discretion and other factors to determine whether it controls the platform or service and therefore is acting as a principal or an agent. Payment for managed services and support is due monthly.

 

Platform Services

 

The Company has standard contracts for its Platform Services, however the statement of work contained in such contracts is unique for each customer. A typical Platform Services contract would provide for some or all of the following types of services being provided to the customer: Data Analytics, Backup and Recovery, through our Platform.

 

The revenue from Platform services is a distinct performance obligation and recognized based on SSP. During the periods presented the Company generated revenue from Platform services on a fixed-price solutions delivery model. Revenues related to fixed-price contracts are recognized as the service is performed using the cost-to-cost method, under which the total value of revenues is recognized based on the percentage that each contract’s total labor cost to date bears to the total expected labor costs. The cost-to-cost method requires estimation of future costs, which is updated as the project progresses to reflect the latest available information; such estimates and changes in estimates involve the use of judgment. The cumulative impact of any revision in estimates is reflected in the financial reporting period in which the change in estimate becomes known and any anticipated losses on contracts are recognized immediately, where appropriate.

 

Our contractual terms and conditions for Software services, Managed Services and Support and Platform services mandate that our services are documented and subject to inspection, testing at the time of delivery to customer. In addition, the Company needs to integrate seamlessly into the customers’ systems. Also, the customer has a right to cancel all, or part of the services rendered if it is not in accordance with statement of work and within the stipulated time. 

 

Contract Balances 

 

The timing of revenue recognition, billings, and cash collections results in billed accounts receivable, unbilled receivables (contract assets), and customer advances and deferred revenue (contract liabilities) on the Consolidated Balance Sheet. Amounts are billed as work progresses in accordance with agreed-upon contractual terms, generally monthly upon achievement of contractual milestones. Generally, billing occurs after revenue recognition, resulting in contract assets. However, we sometimes receive advances or deposits from our customers, particularly on our international contracts, before revenue is recognized, resulting in contract liabilities. These deposits are liquidated when revenue is recognized.

 

11

 

HEALTHCARE TRIANGLE, INC.

Notes To Condensed Consolidated Financial Statements

(Unaudited)

(In thousands except share and per share data)

 

The beginning and ending contract balances were as follows:

 

Schedule of receivables and contract liabilities

 

   March 31,
2025
   December 31,
2024
 
   (In thousands) 
Accounts Receivable   1,907    1,110 

 

Cash and Cash Equivalents

 

The Company considers all highly liquid investments (including money market funds) with an original maturity at acquisition of three months or less to be cash equivalents. The Company maintains cash balances, which may exceed federally insured limits. The Company does not believe that this results in any significant credit risk. An amount of $1.52 million is held in an escrow account with Sichenzia Ross Ference Carmel LLP (SRFC). The funds will be released upon making the S-1 effective no later than 75 days of filing of the 10-K for fiscal 2024.

 

Accounts Receivable

 

The Company extends credit to clients based upon the management’s assessment of their creditworthiness on an unsecured basis. The Company provides an allowance for uncollectible accounts based on historical experience and management evaluation of trend analysis. The Company includes any balances that are determined to be uncollectible in its allowance for doubtful accounts. For the quarter ended March 31, 2025, the Company did not provide an allowance for uncollectible accounts and for the year ended December 31, 2024, the Company provided an allowance for uncollectible accounts of $185. Based on the information available, management believes the Company’s accounts receivable are collectible.

 

Property and Equipment

 

Property and equipment are stated at cost. The Company provides for depreciation of property and equipment using the straight-line method over the estimated useful lives of the related assets ranging from 3 to 7 years. Leasehold improvements are amortized using the straight-line method over the shorter of the lease terms or the useful lives of the improvements. The Company charges repairs and maintenance costs that do not extend the lives of the assets to expenses as incurred.

 

12

 

HEALTHCARE TRIANGLE, INC.

Notes To Condensed Consolidated Financial Statements

(Unaudited)

(In thousands except share and per share data)

 

Allowance for Doubtful Accounts

 

Trade accounts receivable are stated at the amount the Company expects to collect and do not bear interest. The collectability of trade receivable balances is regularly evaluated based on a combination of factors such as customer creditworthiness, past transaction history with the customer, current economic industry trends and changes in customer payment pattern. Additionally, if it is determined that a customer will be unable to fully meet its financial obligation, such as in the case of a bankruptcy filing or other material event impacting its business, a specific allowance for doubtful accounts may be recorded to reduce the related receivable to the amount expected to be recovered.

 

Although we believe that our approach to estimates and judgments regarding our allowance for doubtful accounts is reasonable, actual results could differ and we may be exposed to increases or decreases in required allowances that could be material.

 

Business Combinations

 

As per ASC 805-50 a common-control transaction does not meet the definition of a business combination because there is no change in control over the net assets. The accounting for these transactions are addressed in the “Transactions Between Entities Under Common Control”. The net assets are derecognized by the transferring entity and recognized by the receiving entity at the historical cost of the parent of the entities under common control. Any difference between the proceeds transferred or received and the carrying amounts of the net assets is recognized in equity in the transferring and receiving entities’ separate financial statements and eliminated in consolidation. The change in accounting principle is applied retroactively for all periods presented.

 

We account for business combinations using the acquisition method, which requires the identification of the acquirer, the determination of the acquisition date and the allocation of the purchase price paid by the acquirer to the identifiable tangible and intangible assets acquired, the liabilities assumed, including any contingent consideration and any non-controlling interest in the acquiree at their acquisition date fair values.

 

Goodwill represents the excess of the purchase price over the fair value of net assets acquired, including the amount assigned to identifiable intangible assets. Identifiable intangible assets with finite lives are amortized over their useful lives. Acquisition-related costs are expensed in the periods in which the costs are incurred. The results of operations of acquired businesses are included in our condensed consolidated financial statements from the date of effective control.

 

Valuation of Contingent Earn-out Consideration.

 

Acquisitions may include contingent consideration payments based on the achievement of certain future financial performance measures of the acquired company. Contingent consideration is required to be recognized at fair value as of the acquisition date. We estimate the fair value of these liabilities based on financial projections of the acquired companies and estimated probabilities of achievement. We believe our estimates and assumptions are reasonable, however, there is significant judgment involved. We evaluate, on a routine, periodic basis, the estimated fair value of the contingent consideration and changes in estimated fair value, subsequent to the initial fair value estimate at the time of the acquisition, will be reflected in income or expense in the consolidated statements of operations. Changes in the fair value of contingent consideration obligations may result from changes in discount periods and rates, changes in the timing and amount of revenue and/or earnings estimates and changes in probability assumptions with respect to the likelihood of achieving the various earn-out criteria. Any changes in the estimated fair value of contingent consideration may have a material impact on our operating results.

 

13

 

HEALTHCARE TRIANGLE, INC.

Notes To Condensed Consolidated Financial Statements

(Unaudited)

(In thousands except share and per share data)

 

Earnings (Loss) Per Share

 

Earnings per share (“EPS”) is the amount of earnings attributable to each share of common stock. For convenience, the term is used to refer to either earnings or loss per share. EPS is computed pursuant to Section 260-10-45 of the FASB Accounting Standards Codification. Pursuant to ASC Paragraphs 260-10-45-10 through 260-10-45-16, basic EPS shall be computed by dividing income available to common stockholders (the numerator) by the weighted-average number of common shares outstanding (the denominator) during the period. Income available to common stockholders shall be computed by deducting both the dividends declared in the period on preferred stock (whether or not paid) and the dividends accumulated for the period on cumulative preferred stock (whether or not earned) from income from continuing operations (if that amount appears in the income statement) and also from net income. The computation of diluted EPS is similar to the computation of basic EPS except that the denominator is increased to include the number of additional common shares that would have been outstanding if the dilutive potential common shares had been issued during the period to reflect the potential dilution that could occur from common shares issuable through contingent shares issuance arrangement, stock options or warrants.

 

Fair Value Measurements

 

The Company measures its financial assets at fair value each reporting period using a fair value hierarchy that prioritizes the use of observable inputs and minimizes the use of unobservable inputs when measuring fair value. The hierarchy gives the highest priority to unadjusted quoted prices in active markets for identical assets or liabilities (Level 1 measurements) and the lowest priority to measurements involving significant unobservable inputs (Level 3 measurements). The three levels of the fair value hierarchy are as follows:

 

Level 1—Inputs are observable and reflect quoted prices in active markets for identical assets or liabilities that the Company has the ability to access at the measurement date.

 

Level 2—Inputs other than quoted prices included within Level 1 that are observable, either directly or indirectly.

 

Level 3—Inputs that are unobservable

 

Money market funds and U.S. treasury securities are classified within Level 1 because they are valued using quoted market prices or alternative pricing sources and models utilizing market observable inputs. Other debt securities and investments are classified within Level 2 if the investments are valued using model driven valuations which use observable inputs such as quoted market prices, benchmark yields, reported trades, broker/dealer quotes or alternative pricing sources with reasonable levels of price transparency. In connection with the acquisition of Devcool, Inc., the Company recognized a liability on the acquisition date for the estimated fair value of the contingent consideration based on the probability of achieving certain milestones pursuant to the acquisition agreement. The fair value measurement of the contingent consideration is based on significant unobservable inputs and management judgment; therefore, it is categorized under Level 3 at the balance sheet date in the table below. 

 

14

 

HEALTHCARE TRIANGLE, INC.

Notes To Condensed Consolidated Financial Statements

(Unaudited)

(In thousands except share and per share data)

 

Stock-Based Compensation

 

The Company accounts for stock-based awards to employees and consultants in accordance with applicable accounting principles, which requires compensation expense related to share-based transactions, including employee stock options, to be measured and recognized in the financial statements based on a determination of the fair value of the stock options over the instruments vesting period. Options awarded to purchase shares of common stock issued to non-employees do not need to be remeasured as per ASU 2018-07 principles.

 

The Company adopted the “2020 Stock Incentive Plan” (Plan). The Company has reserved 4,000,000 shares of the Company’s Common stock.

 

Income taxes

 

The provision for income taxes was determined using the asset and liability approach of accounting for income taxes. Under this approach, deferred taxes represent the future tax consequences expected to occur when the reported amounts of assets and liabilities are recovered or paid. The provision for income taxes represents income taxes paid or payable for the current year plus the change in deferred taxes during the period. Deferred taxes result from differences between the financial and tax basis of the Company’s assets and liabilities and are adjusted for changes in tax rates and tax laws when changes are enacted. Valuation allowances are recorded to reduce deferred tax assets when it is more likely than not that a tax benefit will not be realized. Deferred tax assets and liabilities are measured using enacted tax rates applicable in the years in which they are expected to be recovered or settled. The effect on deferred tax assets and liabilities of a change in tax law is recognized in income in the period that includes the enactment date.

 

Advertising Costs

 

The Company expenses advertising cost as incurred. Marketing and advertising expenses for the quarters ended March 31, 2025, and March 31, 2024, were $58 and $268 respectively. 

 

Concentrations

 

Financial instruments that potentially subject the Company to concentrations of credit risk consist principally of cash and trade receivables. Credit risks associated with trade receivables is minimal due to the Company’s customer base which consist of large customer base and ongoing procedures, which monitor the credit worthiness of its customers. For the quarter ended March 31, 2025 and 2024 revenue from the top five customers accounted for approximately 57% and 70% of total revenue respectively. For the quarter ended March 31, 2025, and year ended December 31, 2024, accounts receivable from five major customers accounted for approximately 59% and 63% of the total accounts receivables.

 

The Company maintains cash balances in various financial institutions. The balances are generally insured by the Federal Deposit Insurance Corporation up to $250,000 (valid through March 31, 2025) per institution.

 

As of March 31, 2025, and December 31, 2024, the Company had $2.9 million and $0 million respectively, of uninsured cash balances. The Company has not experienced any losses in such accounts and believes it is not exposed to any significant credit risk on cash.

 

15

 

HEALTHCARE TRIANGLE, INC.

Notes To Condensed Consolidated Financial Statements

(Unaudited)

(In thousands except share and per share data)

 

3) Property and Equipment

 

Property and equipment consisted of the following:

 

Schedule of property and equipment

 

   March 31,
2025
   December 31,
2024
 
   (In thousands) 
Furniture and equipment  $132   $132 
Less:  Accumulated depreciation   (132)   (120)
Net fixed assets  $
0
   $12 

 

Depreciation expenses for the quarter ended March 31, 2025 and 2024 were $12 and $11, respectively.

 

16

 

HEALTHCARE TRIANGLE, INC.

Notes To Condensed Consolidated Financial Statements

(Unaudited)

(In thousands except share and per share data)

 

4) Leases 

 

The Company determines if an arrangement contains a lease at inception. Right of use (“ROU”) assets represent the right to use an underlying asset for the lease term and lease liabilities represent the obligation to make lease payments arising from the lease. ROU assets and liabilities are recognized at the lease commencement date based on the estimated present value of lease payments over the lease term.

 

The Company is currently operating from two office locations leased by SecureKloud. The Company does not have any signed lease agreement in its name. The Company’s principal facility is located in Pleasanton, CA and has another facility in Plainsboro, NJ. Rent expenses were $43 and $33 for the three months ended March 31, 2025, and March 31, 2024, respectively.

 

The Company utilized a portfolio approach in determining the discount rate. The portfolio approach takes into consideration the range of the term, the range of the lease payments, the category of the underlying asset and the Company’s estimated incremental borrowing rate, which is derived from information available at the lease commencement date, in determining the present value of lease payments. The Company also considered its recent debt issuances as well as publicly available data for instruments with similar characteristics when calculating the incremental borrowing rates.

 

Leases with a term of 12 months or less are not recorded on the balance sheet, per the election of the practical expedient noted above. The Company recognizes lease expense for these leases on a straight-line basis over the lease term. The Company recognizes variable lease payments in the period in which the obligation for those payments is incurred. Variable lease payments that depend on an index or a rate are initially measured using the index or rate at the commencement date, otherwise variable lease payments are recognized in the period incurred.

 

5) Other current assets:

 

Particulars  March 31,
2025
   December 31,
2024
 
Other current assets          
Unbilled revenue  $824   $
-
 
Prepaid expenses   232    262 
Others   51    60 
Total  $1,107   $322 

 

6) Due from Affiliates

 

On October 21, 2024, Healthcare Triangle, Inc acquired substantially all of the business, assets, and operations relating to cloud and technology domain of SecureKloud Technologies, Inc a Nevada corporation. The Acquired Assets were acquired by Healthcare Triangle, Inc under an Asset Transfer Agreement, dated October 21, 2024.

 

The consideration for the Acquired Assets consisted of the issuance of 1,600,000 shares of newly designated Series B Convertible Preferred Stock (“Series B Preferred Stock”) which is/are convertible each into 10 common shares at the holder’s option (subject to shareholder’s approval), for a total consideration of USD 7.44 million.

 

This is common control transaction, and the fair value of the assets acquired were calculated as $7,435. The transaction was treated as an asset acquisition and due to the common control nature, the company recorded deemed dividend and the acquired assets at $0, which was the carrying value of the common control seller.

 

On January 1, 2025, the Company entered into a Rental Sublease Agreement with Securekloud Technologies Inc ("SKI") and Master Service Agreement with Securekloud Technologies Inc ("SKI") and Securekloud Technologies Limited ("SKL). As per the Master Services Agreement, SKI and SKL provide technical resources according to the statement of work from the Company. The initial term of the agreement between SKI and the principal lessor is twenty-four months, which is extendable based on mutual consent. The Company received services amounting to $1,132 and $813 for the quarter ended March 31, 2025, and 2024 respectively. The Company has paid for these services during the quarter. 

 

As per the terms of the Rental Sublease Agreement, the cost incurred by SKI on behalf of the Company are settled at cost. The Company received services amounting to $43 and $33 for the quarter ended March 31, 2025, and 2024 respectively. The Company has paid for rent during the quarter.

 

7) Contingent consideration

 

On February 24, 2025, the Company executed a settlement agreement and issued 594,130 common stocks at $0.6733 amounting to $400 and the balance $100 was settled by cash on March 31, 2025.

 

17

 

HEALTHCARE TRIANGLE, INC.

Notes To Condensed Consolidated Financial Statements

(Unaudited)

(In thousands except share and per share data)

 

8) Equity Transactions

 

On February 27, 2025, Healthcare Triangle, Inc. (the “Company”) entered into Securities Purchase Agreements dated February 27, 2025 (the “Purchase Agreement”) with institutional investors (the “Investors”) for the private placement of 36,190,485 units (each a, “Unit”), each Unit consisting of one share of the Company’s common stock (“Common Stock”) or one pre-funded warrant (a “Pre-Funded Warrant”) to purchase one share of common stock, one Series A Warrant (a “Series A Warrant”) to purchase one share of common stock and one Series B Warrant (a “Series B Warrant” and together with the Series A Warrant, the “Purchase Warrants”) to purchase one share of common stock at an offering price of $0.42 per Unit (or $0.41999 per Unit in the case of Units that include pre-funded warrants). The Common Stock, the Pre-Funded Warrants and the Purchase Warrants included in the Units and the Common Stock underlying the Pre-Funded Warrants and the Purchase Warrants are collectively referred to herein as the “Securities” and the Securities, other than the Pre-Funded Warrants, and the Purchase Warrants shall be referred to herein as the “Registrable Securities.” The entire transaction has been priced at the market under Nasdaq rules and closed on February 28, 2025. 

 

The initial exercise price for both the Series A Warrants and Series B Warrants is $0.84 per share and both terminate on the fifth anniversary of the later of (x) effective date of stockholder approval and (y) the earlier of (i) the effective date of the registration statement (the “Registration Statement”) filed by the Company to register the Registerable Securities or (ii) the date that the Registerable Securities can be sold, assigned or transferred without restriction or limitation pursuant to Rule 144 promulgated under the 1933 Act, as amended. The Purchase Warrants may not be exercised until stockholder approval of the exercise of the Purchase Warrants is effective (“Stockholder Approval”). The Company has agreed in the Purchase Agreement to obtain Stockholder Approval within 60 days of the closing date of the offering.

 

The Company received gross proceeds of approximately $15.2 million. Net proceeds to the Company were approximately $13.68 million, after deducting placement agent fees and other expenses payable by the Company.

 

The Company allocated the proceeds between the Common Stock, Pre-Funded Warrants, and Common Warrants on a relative fair value basis and recorded the amount allocated to the Common Warrants within additional paid-in capital on the accompanying consolidated balance sheet as the Common Warrants met all the criteria for equity classification. As the Common Warrants were equity classified, they do not require subsequent remeasurement after the issuance.

 

The Common Warrants contain standard adjustments to the exercise price including for stock splits, stock dividend, rights offerings and pro rata distributions.

 

Black Scholes warrant fair value:

 

Instrument  Shares/ Warrants   Fair value   Gross Proceeds   Expenses on fund raising   Net Proceeds 
Common Stock   7,017,429    2,947    95    (10)   85 
Pre-funded Warrants   29,173,056    12,253    395    (40)   355 
Series A Warrants   361,904,850                     
Series B Warrants   1,085,714,550    456,000    14,710    (1,474)   13,236 
         471,200    15,200    (1,524)   13,676 

 

Preferred Stock

 

The Company’s Certificate of Incorporation provides for a class of its authorized stock known as preferred stock, comprised of 10,000,000 shares, $0.00001 par value per share (the “Preferred Stock”), issuable from time to time in one or more series.

 

With respect to payment of dividends and distribution of assets upon liquidation, dissolution, or winding up of the Corporation, whether voluntary or involuntary, the Series A Convertible Preferred Stock will rank: (i) senior to all other classes or series of capital stock of the Corporation now existing or hereafter authorized, classified or reclassified, and (ii) junior to all Indebtedness of the Corporation now existing or hereafter authorized (including Indebtedness convertible into Common Stock).

 

The holders of the Series A Convertible Preferred Stock shall not be entitled to receive dividends paid on the Corporation's Common Stock.

 

With respect to payment of dividends and distribution of assets upon liquidation, dissolution, or winding up of the Corporation, whether voluntary or involuntary, the Series B Convertible Preferred Stock will rank: (i) senior to all other classes or series of capital stock of the Corporation now existing or hereafter authorized, classified or reclassified, and (ii) junior to all Indebtedness of the Corporation now existing or hereafter authorized (including Indebtedness convertible into Common Stock).

 

The holders of the Series B Convertible Preferred Stock shall not be entitled to receive dividends paid on the Corporation's Common Stock.

 

Series A Preferred Stock

 

On March 12, 2025, the Board of Directors of the Company approved the issuance of 14,000 Series A Preferred Stock to Mr Suresh Venkatachari.

 

Series B Preferred Stock

 

On October 21, 2024, the Company acquired the customer contracts from SecureKloud Technologies, Inc (an affiliate) and in consideration for the acquired assets, issued 1,600,000 shares of Series B Convertible Preferred Stock (“Series B Preferred Stock”) which is/are convertible each into 10 common shares at the holder’s option. The Series B Preferred Stock were valued at USD 7.44 million.

 

18

 

HEALTHCARE TRIANGLE, INC.

Notes To Condensed Consolidated Financial Statements

(Unaudited)

(In thousands except share and per share data)

 

9) Convertible Notes

 

A. L1 Capital

 

During the quarter ending March 31, 2025, the Company converted $875,000 principal and $315,865 towards interest and conversion fees on the L1 Capital convertible note.

 

Date  Loan   Conversion price   No of shares 
1/7/2025  $125,000    0.62    270,362 
2/3/2025   200,000    0.58    464,681 
2/14/2025   175,000    0.41    583,076 
2/18/2025   175,000    0.41    584,102 
2/21/2025   200,000    0.38    726,818 
Total  $875,000         2,629,039 

 

B. Pioneer Garage

 

During the quarter ending March 31, 2025, the Company repaid convertible note amounting to $1,500,000.

 

Convertible Note  March 31,
2025
   December 31,
2024
 
Short-term borrowing  $
           -
   $2,061 
Long-term borrowing   
-
    
-
 
Convertible note outstanding  $
-
   $2,061 

 

Convertible Note  March 31,
2025
   December 31,
2024
 
Convertible notes payable 1  $
        -
   $2,375 
Less: discount 2   
-
    314 
Notes payable, net of discount 1-2   
-
    2,061 
Notes payable, current portion, net of discount   
-
    2,061 
Notes payable, long-term portion, net of discount  $
-
   $
-
 

 

B. Common Stock Warrants

 

On December 28, 2023, the Company issued Senior Secured 15% Original Issue Discount Convertible Promissory Note for an initial amount of $2,000,000 of convertible notes with an annual interest rate of 18% and a maturity term of 18 months. In connection with this issuance, the Company also issued 357,500 warrants, each allowing the holder to purchase shares of the Company’s common stock at an exercise price of $3.44688, exercisable until December 28, 2028.

 

On December 28, 2023, the Company issued a convertible note to the investor in the principal amount of $2.0 million which resulted in gross proceeds to the Company of $1.7 million (the “First Tranche Note”) and Warrants to purchase up to an aggregate of 357,500 Warrant Shares (the “First Tranche Warrants”). The First Tranche Note, and the First Tranche Warrants have an initial fixed conversion and exercise price of $3.44688 per share, respectively, subject to adjustment. The First Tranche Warrants carry a 5-year term and, if not exercised, will terminate on December 28, 2028.

 

           Weighted     
       Weighted   Average     
       Average   Remaining   Aggregate 
   Number of   Exercise   Contractual   Intrinsic 
Warrants  Warrants   price   Term   value 
Outstanding on January 1, 2025   967,256   $7.99    3.05   $3,785 
Granted   
    
    
    
 
Excised   
    
    
    
 
Forfeited or expired   
    
    
    
 
Outstanding on March 31, 2025   967,256   $7.99    2.80   $3,785 
Exercisable on March 31, 2025   424,741   $7.99    2.57   $1,662 

 

19

 

HEALTHCARE TRIANGLE, INC.

Notes To Condensed Consolidated Financial Statements

(Unaudited)

(In thousands except share and per share data)

 

           Weighted     
       Weighted   Average     
       Average   Remaining   Aggregate 
   Number of   Exercise   Contractual   Intrinsic 
Warrants  Warrants   price   Term   value 
Outstanding on January 1, 2024   967,256   $7.99    4.07   $3,785 
Granted   
    
    
    
 
Excised   
    
    
    
 
Forfeited or expired   
    
    
    
 
Outstanding on March 31, 2024   967,256   $7.99    3.82   $3,785 
Exercisable on March 31, 2024   231,290   $7.99    3.82   $1,144 

 

The following table summarizes the activities for our unvested warrants for the three months ended March 31, 2025.  

 

          Weighted
average Grant
Date Fair
 
    Number of
Warrants
    Value Per
warrant
 
Unvested on January 1, 2025     590,878     $ 3.51  
Granted            
Vested     (48,363 )     3.91  
Forfeited            
Unvested on March 31, 2025     542,515     $ 3.47  

 

The following table summarizes the activities for our unvested warrants for the year ended December 31, 2024.  

 

       Weighted
average Grant
Date Fair
 
   Number of
Warrants
   Value Per
warrant
 
Unvested on January 1, 2024   784,329   $3.91 
Granted   
    
 
Vested   (48,363)   3.91 
Forfeited   
    
 
Unvested on March 31, 2024   735,966   $3.91 

 

20

 

HEALTHCARE TRIANGLE, INC.

Notes To Condensed Consolidated Financial Statements

(Unaudited)

(In thousands except share and per share data)

 

C. Short term borrowing

 

Particulars  March 31,
2025
   December 31,
2024
 
Short Term Borrowing        
Seacoast Business Funding  $775   $589 
Convertible note   
-
    2,061 
Total  $775   $2,650 

 

(i) Seacoast Business Funding

 

The Company obtained a credit facility from Seacoast business funding (SBF), a division of Seacoast National Bank during the year ended December 31, 2022. The funding is against the accounts receivable of the company and its subsidiary. The SBF facility incurs an interest rate 8.5% for the quarter ended March 31, 2025 and 8.9% for the quarter ended December 31, 2024. The value of invoices funded during the quarter ending March 31, 2025, was $1,938 and $2,022 for the quarter ending December 31, 2024. The maximum amount of advance under the purchase agreement is $10 million and the bank may advance upto 90% of the unpaid domestic outstanding accounts under the re-course agreement.

 

The balance as of March 31, 2025, is $775 and $589 for the period ending December 31, 2024.

 

10) Other current liability

 

Particulars  March 31,
2025
   December 31,
2024
 
Other current liability        
Payroll  $304   $463 
Audit fees   45    193 
Insurance   137    217 
Other   329    513 
Total  $815   $1,386 

 

11) Provision for Income Taxes

 

The Company accounts for income taxes in accordance with FASB ASC Topic 740, Income Taxes. Deferred income taxes reflect the net tax effects of temporary differences between the carrying amounts of assets and liabilities for financial reporting purposes and the amounts used for income tax purposes. Management evaluates all available evidence about future taxable income and other possible sources of realization of deferred tax assets. A valuation allowance is established to reduced tax assets to an amount that represents management’s best estimate of the amount of such deferred tax assets that more likely than not will be realized. To the extent the Company establishes a valuation allowance or increased the allowance in any given period, an expense is recognized within the provision for income taxes in the statement of income.

 

The Company recognizes the tax benefit from uncertain tax position only if it is more likely than not that the tax position will be sustained on examination by the tax authorities, based on the technical merits of the position. The tax benefit is measured based on the largest benefit that has a greater than 50 percent likelihood of being realized upon ultimate settlement. The Company recognizes interest and penalties related to income tax matters as other expense in the statement of income. Based on management’s evaluations, there are no uncertain tax positions requiring recognition as of the date of these financial statements.

 

21

 

HEALTHCARE TRIANGLE, INC.

Notes To Condensed Consolidated Financial Statements

(Unaudited)

(In thousands except share and per share data)

 

The components of the Company’s net deferred tax assets as of March 31, 2025, and December 31, 2024, were as follows (in thousands):

 

   March 31,
2025
   December 31,
2024
 
   (In thousands) 
Deferred tax assets:        
Net Operating loss carry-forward  $476   $1,439 
Add back:          
Stock-based compensation   (10)   (30)
Depreciation and amortization   3    (249)
Impairment expense   
-
    
 
Bad debt   
-
    (48)
Fair value of warrant   
-
    (43)
Gain on revaluation   
 
    
 
Other income   31    
-
 
Total deferred tax asset   500    1,069 
Less: valuation allowance  $(500)  $(1,069)
Deferred tax asset. net of valuation allowance   
    
 
Deferred tax liabilities   
    
 
Net deferred tax asset   
    
 

 

The Company’s current tax expense is nil.

 

The Company’s federal and state income tax returns are generally subject to possible examination by the taxing authorities until the expiration of the related statute of limitations on those tax returns which is generally three years from the original filing deadline. The Company regularly reviews its deferred tax assets for recoverability based on historical taxable income, projected future taxable income, the expected timing of the reversals of existing taxable temporary differences and tax planning strategies. The Company’s judgment regarding future profitability may change due to many factors, including future market conditions and the ability to successfully execute the business plans and/or tax planning strategies. Should there be a change in the ability to recover deferred tax assets, the Company’s income tax provision would increase or decrease in the period in which the assessment is changed.

 

12) New Accounting Pronouncements

 

In March 2024, the FASB issued ASU No. 2024-01, “Compensation—Stock Compensation (Topic 718): Scope Applications of Profits Interests and Similar Awards” (“ASU 2024-01”). ASU 2024-01 adds an example to Topic 718 which illustrates how to apply the scope guidance to determine whether profits interests and similar awards should be accounted for as share-based payment arrangements under Topic 718 or under other U.S. GAAP. ASU 2024-01 is effective for annual periods beginning after December 15, 2025, although early adoption is permitted. Upon adoption, ASU 2024-01 is not expected to have an impact on the Company’s consolidated financial statements.

 

In November 2024, the FASB issued ASU No. 2024-03, “Income Statement - Reporting Comprehensive Income - Expense Disaggregation Disclosures (Subtopic 220-40).” This standard requires disclosure of specific information about costs and expenses and becomes effective January 1, 2027. The Company is currently evaluating the impact of this standard on our consolidated financial statements and related disclosures.

 

In November 2024, the FASB issued ASU 2024-04, “Debt - Debt with Conversions and Other Options (Subtopic 470-20): Induced Conversions of Convertible Debt Instruments” (“ASU 2024-04”). ASU 2024-04 clarifies the requirements for determining whether certain settlements of convertible debt instruments, including convertible debt instruments with cash conversion features or convertible debt instruments that are not currently convertible, should be accounted for as an induced conversion. The requirements of ASU 2024-04 are effective for the Company for fiscal years beginning after December 15, 2025, and interim periods within those periods. The Company is currently evaluating the impact of this standard on our consolidated financial statements and related disclosures.

 

22

 

HEALTHCARE TRIANGLE, INC.

Notes To Condensed Consolidated Financial Statements

(Unaudited)

(In thousands except share and per share data)

 

13) Legal Matters

 

The Company is not involved in any action, arbitration and/or other legal proceedings that it expects to have a material adverse effect on the business, financial condition, results of operations or liquidity of the Company. All legal cost is expensed as incurred.

 

14) Share Based Compensation

 

We estimate the fair value of our stock options using the Black-Scholes option pricing model. This requires the input of subjective assumptions, including the fair value of our underlying common stock, the expected term of stock options, the expected volatility of the price of our common stock, risk-free interest rates, and the expected dividend yield of our common stock, the most critical of which, prior to our IPO, was the estimated fair value of common stock. The assumptions used in our option pricing model represent our best estimates. These estimates involve inherent uncertainties and the application of management’s judgment. If factors change and different assumptions are used, our stock-based compensation expense could be materially different in the future. The resulting fair value, net of actual forfeitures, is recognized on a straight-line basis over the period during which an employee is required to provide service in exchange for the award.

 

These assumptions used in the Black-Scholes option pricing model, other than the fair value of our common stock, are estimated as follows:

 

Expected volatility. Since a public market for our common stock did not exist prior to our IPO in October 2021 and, therefore, we do not have an extensive trading history of our common stock, we estimated the expected volatility based on the volatility of similar publicly-held entities (guideline companies) over a period equivalent to the expected term of the awards. In evaluating the similarity of guideline companies to us, we considered factors such as industry, stage of life cycle, size, and financial leverage. We intend to continue to consistently apply this process using the same or similar guideline companies to estimate the expected volatility until sufficient historical information regarding the volatility of the share price of our common stock becomes available.

 

Expected term. We estimate the expected term using the simplified method, as we do not have sufficient historical exercise activity to develop reasonable expectations about future exercise patterns and post-vesting employment termination behavior. The simplified method calculates the average period the stock options are expected to remain outstanding as the midpoint between the vesting date and the contractual expiration date of the award.

 

  Risk-free interest rate. The risk-free interest rate is based on the U.S. Treasury yield curve in effect at the time of grant for maturities corresponding with the expected term of the option.

 

Expected dividend yield. We have never declared or paid any dividends and do not presently plan to pay dividends in the foreseeable future. Consequently, we use an expected dividend yield of zero.

 

23

 

HEALTHCARE TRIANGLE, INC.

Notes To Condensed Consolidated Financial Statements

(Unaudited)

(In thousands except share and per share data)

 

We are required to estimate the fair value of the common stock underlying our stock-based awards when performing fair value calculations

 

Historically for all periods prior to our IPO, given the absence of a public trading market for our common stock, and in accordance with the American Institute of Certified Public Accountants Practice Guide, Valuation of Privately-Held Company Equity Securities Issued as Compensation, we exercised reasonable judgment and considered numerous objective and subjective factors to determine the best estimate of the fair value of our common stock including:

 

  contemporaneous valuations performed at periodic intervals by unrelated third-party specialists
     
  our actual operating and financial performance.
     
  relevant precedent transactions involving our capital stock;
     
  likelihood of achieving a liquidity event, such as an initial public offering or a sale of our company given prevailing market conditions and the nature and history of our business;
     
  market multiples of comparable companies in our industry;
     
  stage of development.
     
  industry information such as market size and growth;
     
  illiquidity of stock-based awards involving securities in a private company; and

 

In valuing our common stock prior to our IPO, our board of directors determined the enterprise value of our company using both the income approach and market approach valuation methods. The income approach estimates value based on the expectation of future cash flows that a company will generate. These future cash flows are discounted to their present values using a discount rate based on the cost of capital at a company’s stage of development. The market approach estimates value based on a comparison of the subject company to comparable public companies in a similar line of business. From the comparable companies, a representative market value multiple is determined and then applied to the subject company’s financial results to estimate the enterprise value of the subject company.

 

A summary of option activity under the employee share option plan as of March 31, 2025, and changes during the year then period is presented below.

 

Schedule of stock option activity

 

   Options   Shares of Stock 
   No. of
Options
   Weighted
Average
Price
   No. of
Shares
   Weighted
Average
Price
   Total 
Balance available under the plan as at January 1, 2025   592,252    
        —
    
     —
    
      —
    592,252 
Granted   
    
    
    
    
 
Cancelled/expired/exercised   2,300    4    
    
    2,300 
Additions to the plan   3,138,236                   3,138,236 
Balance available under the plan as of March 31, 2025   3,732,788    
    
    
    3,732,788 

 

A summary of option activity under the employee share option plan as of March 31, 2024, and changes during the year then ended is presented below.

 

   Options   Shares of Stock 
   No. of
Options
   Weighted
Average Price
   No. of
Shares
   Weighted
Average Price
   Total 
Balance available under the plan on January 1, 2024   538,265    
   —
    
      —
    
    538,265 
Granted   (20,000)  $
1,78
              (20,000)
Cancelled/expired   17,110                   17,110 
Additions to the plan   
-
    
-
    
-
    
-
    
-
 
Balance available under the plan on March 31, 2024   535,375    
 
    
 
    
 
    535,375 

 

24

 

HEALTHCARE TRIANGLE, INC.

Notes To Condensed Consolidated Financial Statements

(Unaudited)

(In thousands except share and per share data)

 

The following table summarizes the activities for our unvested options for the year ended March 31, 2025

 

   Number of   Weighted
average
Grant Date
Fair Value
 
   Shares   Per Share 
Unvested on January 1, 2025   35,849   $1.88 
Granted   
-
    
-
 
Vested   (35,849)   1.88 
Forfeited   
-
    
-
 
Unvested on March 31, 2025   
-
   $
-
 

 

The following table summarizes the activities for our unvested options for the year ended March 31, 2024

 

   Number of   Weighted
average
Grant Date
Fair Value
 
   Shares   Per Share 
Unvested on January 1, 2024   46,928   $2.24 
Granted   -    
-
 
Vested   (31,496)   0.80 
Forfeited   (3,000)   3.50 
Unvested on March 31, 2024   75,424   $1.59 

 

The weighted-average grant date fair value of options granted during the quarter ended March 31, 2025, was $0 and $0 during the quarter ended March 31, 2024. The total fair value of the vested options as of March 31, 2025, and March 31, 2024, were $ 911 and $576 respectively.

 

As of March 31, 2025, there was $36 of unrecognized share-based compensation expense related to unvested options. This unrecognized compensation expense is expected to be recognized over a weighted-average period of approximately two years based on vesting under the award service conditions.

 

Schedule of assumptions

 

Fair value assumptions  2024   2023 
Expected volatility   45%-52 %   45%-52 %
Expected terms (in years)   4    4 
Risk-free interest rate   4.70%-5.70 %   4.60%-5.46 %
Dividend yield   0%   0%

 

25

 

HEALTHCARE TRIANGLE, INC.

Notes To Condensed Consolidated Financial Statements

(Unaudited)

(In thousands except share and per share data)

 

15) Net Income per share

 

The Company presents basic and diluted earnings per share (“EPS”) data for its common stock. Basic EPS is calculated by dividing the net income attributable to stockholders of the Company by the weighted average number of shares of common stock outstanding during the period. Diluted EPS is determined by adjusting the net income attributable to stockholders of the Company and the weighted average number of shares of common stock outstanding during the period for the effects of all dilutive potential common shares, including awards under stock-based compensation arrangements.

 

The Company’s unvested restricted stock awards are considered participating securities under FASB Codification topic, Earnings Per Share, because they entitle holders to non-forfeitable rights to dividends until the awards vest or are forfeited. When a company has a security that qualifies as a “participating security,” the Codification requires the use of the two-class method when computing basic EPS. The two-class method is an earnings allocation formula that determines EPS for each class of common stock and participating security according to dividends declared (or accumulated) and participation rights in undistributed earnings. In determining the amount of net income to allocate to common stockholders, income is allocated to both common stock and participating securities based on their respective weighted average shares outstanding for the period, with net income attributable to common stockholders ultimately equally net income less net income attributable to participating securities. Diluted EPS for the Company’s common stock is computed using the more dilutive of the two-class method or the treasury stock method.

 

Schedule of earning per share

 

   Three Months Ended
March 31,
 
   2025   2024 
Net income attributable to common stockholders  $(1,700)  $(1,862)
Weighted average shares outstanding – basic and diluted   9,843,821    4,455,245 
Basic and diluted EPS   (0.17)   (0.42)

 

16) Subsequent Events

 

1. The Company received the notice of effectiveness of Form S-1 on May 14, 2025.

 

2. The Company has issued 29,173,056 Common stocks to holders of the pre-funded warrants.

 

3. The Company has issued 316,206,975 Common stock to holders of Series B warrants on exercise of the “zero exercise price option”

 

26

 

Item 2. Management’s discussion and analysis of financial condition and results of operations.

 

The following discussion summarizes the significant factors affecting the operating results, financial condition, liquidity, and cash flows of our Company as of and for the periods presented below. The following discussion and analysis should be read in conjunction with the condensed consolidated financial statements and the related notes thereto, and the consolidated financial statements and the related notes thereto all included elsewhere in this prospectus. The statements in this discussion regarding industry outlook, our expectations regarding our future performance, liquidity, and capital resources, and all other non-historical statements in this discussion are forward-looking statements and are based on the beliefs of our management, as well as assumptions made by, and information currently available to, our management. Actual results could differ materially from those discussed in or implied by forward looking statements as a result of various factors, including those discussed below and elsewhere in this report, and in the sections entitled “Special Note Regarding Forward-Looking Statements” and “Risk Factors” contained in the Company’s final prospectus for its initial public offering filed with the Securities and Exchange Commission (“SEC”).

 

Overview

 

Healthcare Triangle, Inc. (the “Company”) is a leading healthcare information technology company focused on advancing innovative, industry-transforming solutions in the areas of cloud services, data science, professional and managed services for the Healthcare and Life Sciences industry.

 

The Company was formed on October 29, 2019, as a Nevada corporation and then converted into a Delaware corporation on April 24, 2020, to provide IT and data services to the Healthcare and Life Sciences (“HCLS”) industry. The business commenced on January 1, 2020, after SecureKloud Technologies Inc, transferred its Life Sciences business to us. As of March 31, 2024, we had a total of 44 full time employees, 41 sub-contractors, including 24 certified cloud engineers, 6 Epic Certified EHR experts and 11 MEDITECH Certified EHR experts. Many of the senior management team and the members of our board of directors hold advanced degrees and some are leading experts in the field of technology, investment banking and public markets.

 

During the quarter ended March 31, 2025, the Company generated revenues of approximately $3.7 million compared to revenue of $4.1 million for the quarter ended March 31, 2024 which represents a decrease of $0.4 million or 10% compared to the previous year.

 

Our approach leverages our proprietary technology platforms, extensive industry knowledge, and healthcare domain expertise to provide solutions and services that reinforce healthcare progress. Through our platform, solutions, and services, we support healthcare delivery organizations, healthcare insurance companies, pharmaceutical, and Life Sciences, biotech companies, and medical device manufacturers in their efforts to improve data management, develop analytical insights into their operations, and deliver measurable clinical, financial, and operational improvements.

 

27

 

We offer a comprehensive suite of software, solutions, platforms, and services that enables some of the world’s leading healthcare and pharma organizations to deliver personalized healthcare, precision medicine, advances in drug discovery, development and efficacy, collaborative research and development, respond to real-world evidence, and accelerate their digital transformation. We combine our expertise in the healthcare technology domain, cloud technologies, DevOps and automation, data engineering, advanced analytics, security, compliance, and governance to deliver platforms and solutions that drive improved results in the complex workflows of Life Sciences, biotech, healthcare providers, and payers. Our differentiated solutions, enabled by our intellectual property and delivered as a service, provide advanced analytics, data science applications, and data aggregation in these highly regulated environments in a more compliant, secure, and cost-effective manner to our customers. 

 

Our deep expertise in healthcare allows us to reinforce our clients’ progress by accelerating their innovation. Our healthcare IT services include Electronic Health Records (EHR) and software implementation, optimization, extension to community partners, as well as application managed services, and backup and disaster recovery capabilities on public cloud. Our 24x7 managed services are used by hospitals and health systems, payers, Life Sciences, and biotech organizations in their effort to improve health outcomes and deliver deeper, more meaningful patient and consumer experiences. Through our services, our customers achieve a return on investment in their technology by delivering measurable improvements. Combined with our software and solutions, our services provide clients with an end-to-end partnership for their technology innovation.

 

Our Business Model

 

The majority of our revenue is generated by our full-time employees who provide software services and Managed Services and Support to our clients in the Healthcare and Life Sciences industry. Our software services include strategic advisory, implementation and development services and Managed Services and Support include post implementation support and cloud hosting.

 

Key Factors of Success

 

We believe that our future growth, success, and performance are dependent on many factors, including those mentioned below. While these factors present significant opportunities for us, they also represent the challenges that we must successfully address in order to grow our business and improve our results of operations.

 

Investment in scaling the business

 

We need to continuously invest in sales, and marketing to promote our solutions to new and existing customers in various geographies, and other operational and administrative functions in systems, controls and governance to support our expected growth and our transition to a public company. We anticipate that our employee strength will increase because of these investments.

 

Adoption of our solutions by new and existing customers

 

We believe that our ability to increase our customer base will enable us to drive growth. Most of our customers initially deploy our solutions within a division or geography and may only initially deploy a limited set of our available solutions. Our future growth is dependent upon our existing customers’ continued success and renewals of our solutions agreements, deployment of our solutions to additional divisions or geographies and the purchase of subscriptions to additional solutions. Our growth is also dependent on the adoption of our solutions by new customers. Our customers are large organizations who typically have long procurement cycles which may lead to declines in the pace of our new customer additions.

 

28

 

Subscription services adoption

 

The key factor to our success in generating substantial recurring subscription revenues in future will be our ability to successfully market and persuade new customers to adopt our SaaS offerings. We are in the early stages of marketing our SaaS offerings such as DataEz, CloudEz and Readabl.AI, and do not yet have enough information about our competition or customer acceptance to determine whether or not recurring subscription revenue from these offerings will have a material impact on our revenue growth.

 

Mix of solutions and software services revenues

 

Another factor to our success is the ability to sell our solutions to the existing software services customers. During the initial period of deployment by a customer, we generally provide a greater number of services including advisory, implementation and training. At the same time, many of our customers have historically purchased our solutions after the deployment. Hence, the proportion of total revenues for a customer associated with software services is relatively high during the initial deployment period. While our software services help our customers achieve measurable improvements and make them stickier, they have lower gross margins than solution-based revenue. Over time, we expect the revenues to shift towards recurring and subscription-based revenues.

 

Components of Results of Operations

 

Revenues

 

We provide our services and manage our business under these operating segments:

 

  Software services

 

  Managed services and support

 

  Platform services

 

Software Services

 

The Company earns revenue primarily through the sale of software services that is generated from providing strategic advisory, implementation, and development services. The Company enters into Statement of Work (SOW) which provides for service obligations that need to be fulfilled as agreed with the customer. The majority of our software services arrangements are billed on a time and materials basis and revenues are recognized over time based on time incurred and contractually agreed upon rates. Certain software services revenues are billed on a fixed fee basis and revenues are typically recognized over time as the services are delivered based on time incurred and customer acceptance. We recognize revenue when we have the right to invoice the customer using the allowable practical expedient under ASC 606-10-55-18 since the right to invoice the customer corresponds with the performance obligations completed.

 

29

 

Managed Services and Support

 

Managed Services and Support include post implementation support and cloud hosting. Managed Services and Support are a distinct performance obligation. Revenue for Managed Services and Support is recognized ratably over the life of the contract.

 

Platform Services

 

Platform Services from CloudEz, DataEz are offered both as a solution delivery model and as Software as a Service (SaaS) on a subscription model. readbl.ai is offered only as Software as a Service (SaaS) on a subscription model.

 

The revenue from solutions delivery model contains a series of separately identifiable and distinct services that represent performance obligations that are satisfied over time. During the periods presented the company generated Platform revenue on SaaS, which is recurring revenue.

 

Our SaaS agreements are generally non-cancellable during the term, although customers typically will have the right to terminate their agreements for cause in the event of material breach.

 

SaaS revenues will be recognized ratably over the respective non-cancellable subscription term because of the continuous transfer of control to the customer. Our subscription arrangements will be considered service contracts, and the customer will not have the right to take possession of the software Segment wise revenue breakup.

 

Cost of Revenue

 

Cost of revenue consists primarily of employee-related costs associated with the rendering of our services, including salaries, benefits and stock-based compensation expense, the cost of subcontractors, travel costs, cloud hosting charges and allocated overhead the cost of providing professional services is significantly higher as a percentage of the related revenues than for our subscription services due to the direct labor costs and costs of subcontractors. Our business and operational models are designed to be highly scalable and leverage variable costs to support revenue-generating activities. 

 

While we may grow our headcount overtime to capitalize on our market opportunities, we believe our increased investment in automation, electronic health record integration capabilities, and economies of scale in our operating model, will position us to grow our platform solutions revenue at a greater rate than our cost of revenue.

 

Operating Expenses

 

Research and Development

 

Research and development expense (majorly our investment in innovation) consists primarily of employee-related expenses, including salaries, benefits, incentives, employment taxes, severance, and equity compensation costs for our software developers, engineers, analysts, project managers, and other employees engaged in the development and enhancement of our cloud-based platform applications. Research and development expenses also include certain third-party consulting fees. Our research and development expense excludes any depreciation and amortization.

 

We expect to continue our focus on developing new product offerings and enhancing our existing product offerings. As a result, we expect our research and development expense to increase in absolute dollars, although it may vary from period to period as a percentage of revenue.

 

30

 

Sales and Marketing

 

Sales and marketing expense consists primarily of employee-related expenses, including salaries, benefits, commissions, travel, discretionary incentive compensation, employment taxes, severance, and equity compensation costs for our employees engaged in sales, sales support, business development, and marketing. Sales and marketing expense also includes operating expenses for marketing programs, research, trade shows, and brand messages, and public relations costs.

 

We expect our sales and marketing expenses to continue to increase in absolute dollar terms as we strategically invest to expand our business, although it may vary from period to period as a percentage of total revenues.

 

General and Administrative

 

Our general and administrative expenses consist primarily of employee-related expenses including salaries, benefits, discretionary incentive compensation, employment taxes, severance, and stock-based compensation expenses, for employees who are responsible for management information systems, administration, human resources, finance, legal, and executive management. The general and administrative expenses also include occupancy expenses (including rent, utilities, and facilities maintenance), professional fees, consulting fees, insurance, travel, contingent consideration, transaction costs, integration costs, and other expenses. Our general and administrative expenses exclude depreciation and amortization.

 

In the nearest future, we expect our general and administrative expenses to continue to increase to support business growth. Over the long term, we expect general and administrative expenses to decrease as a percentage of revenue.

 

Depreciation and Amortization Expenses

 

Our depreciation and amortization expense consists primarily of depreciation of fixed assets, amortization of Customer relationship and capitalized software development costs, and amortization of intangible assets. We expect our depreciation and amortization expense to increase as we expand our business organically and through acquisitions. 

 

Other Income (Expense), Net

 

Other income (expense), net consists of finance cost and gains or losses on foreign currency.

 

Deferred revenues

 

Advanced billings to clients in excess of revenue earned are recorded as deferred revenue until the revenue recognition criteria are met.

 

Unbilled accounts receivable

 

Unbilled accounts receivable is a contract asset related to the delivery of our professional services for which the related billings will occur in a future period. Unbilled receivables are classified as accounts receivable on the consolidated balance sheet. Although we believe that our approach to estimates and judgments regarding revenue recognition is reasonable, actual results could differ and we may be exposed to increases or decreases in revenue that could be material.

 

31

 

Provision for Income Taxes

 

Provision for income taxes consists of federal and state income taxes in the United States, including deferred income taxes reflecting the net tax effects of temporary differences between the carrying amounts of assets and liabilities for financial reporting purposes.

 

Results of Operations

 

The following tables set forth selected consolidated statements of operations data and such data as a percentage of total revenues for each of the periods indicated:

 

 

   Three Months Ended
March 31,
 
   2025   % Sales   2024   % Sales 
   (In thousands)   (In thousands) 
Revenue  $3,704    100%  $4,109    100%
Cost of Revenue (exclusive of depreciation /amortization)   3,375    91%   3,095    75%
Research and Development   144    4%   127    3%
Sales and Marketing   373    10%   883    21%
General and Administrative   1,198    32%   1,181    29%
Depreciation and Amortization   12    0%   536    13%
Other Income   (111)   3%       0%
Interest expense   413    11%   149    4%
Income tax   -    0%   -    0%
Net income (loss)  $(1,700)   (46)%  $(1,862)   (45)%

 

Three Months Ended March 31, 2025 and March 31, 2024.

 

Revenue from operations

 

   Three Months Ended
March 31,
   Changes 
   2025   2024   Amount   % 
   (In thousands, except percentages) 
Revenue  $3,704   $4,109   $(405)   (10)%

 

Revenue decreased by $0.4 million, or 10% to $3.7 million for the quarter ended March 31, 2025, as compared to $4.1 million for the quarter ended March 31, 2024. Revenue from Software Services, Managed Services and support and Platform services have reduced resulting in net decrease in revenue. The Software Services are typically short-term engagements to provide software consulting and development services, which do not require continual third-party maintenance. Managed Services and Support such as cloud hosting, and cloud disaster recovery requires continuous monitoring.

 

Our top 5 customers accounted for 57% of the revenue in quarter ended March 31, 2025, and 70% during quarter ended March 31, 2024, respectively.

 

The following table has the breakdown of our revenues for the quarter ended March 31, 2025, and 2024 for each of our top 5 customers.

 

32

 

Top Five Customers Revenue for three months ended March 31 2025 and 2024.

 

2025 

 

(In thousands, except percentages)    
Customer  Amount   % of Revenue 
Customer 1  $754    20%
Customer 2   659    18%
Customer 3   266    7%
Customer 4   233    6%
Customer 5  $188    5%

 

2024 

 

(In thousands, except percentages)    
Customer  Amount   % of Revenue 
Customer 1  $807    20%
Customer 2   720    18%
Customer 3   490    12%
Customer 4   476    12%
Customer 5  $332    8%

 

The following table provides details of Customer 1 revenue by operating segments:

 

   Three Months Ended
March 31,
   Changes 
   2025   2024   Amount   % 
   (In thousands, except percentages) 
Software services  $721   $787   $(66)   (8%)
Managed services and support   33    20    13    65%
Platform services                
Total Revenue  $754   $807   $(53)   (7%)

 

Revenue from Customer 1 decreased by $0.05 million, or 7% to $0.75 million for the quarter ended March 31, 2025, as compared to $0.80 million for the quarter ended March 31, 2024. Software services revenue decreased by $0.06 million or 8% to $0.72 million for the quarter ended March 31, 2025, as compared to $0.78 million for the quarter ended March 31, 2024. Managed Services and Support revenue increased by $0.01 million, or 65% to $0.03 million for the quarter ended March 31, 2025, as compared to $0.02 million for the quarter ended March 31, 2024.

 

Cost of Revenue (exclusive of depreciation /amortization)

 

   Three Months Ended
March 31,
   Changes 
   2025   2024   Amount   % 
   (In thousands, except percentages) 
Cost of revenue (exclusive of depreciation/amortization)  $3,375   $3,095   $280    9%

 

Cost of revenue, excluding depreciation and amortization increased by $0.28 million, or 9%, to $3.3 million for the quarter ended March 31, 2025, as compared to $3.0 million for the quarter ended March 31, 2024.

 

33

 

Research and Development

 

   Three Months Ended
March 31,
   Changes 
   2025   2024   Amount   % 
   (In thousands, except percentages) 
Research and development  $144   $127   $17    13%

 

Research and development expenses increased by $0.01 million, or 13% to $0.14 million for the quarter ended March 31, 2025, as compared to $0.0.12 million for the quarter ended March 31, 2024.

 

Sales and Marketing

 

   Three Months Ended
March 31,
   Changes 
   2025   2024   Amount   % 
   (In thousands, except percentages) 
Sales and marketing  $373   $883   $(510)   (58)%

 

Sales and marketing expenses decreased by $0.51 million, or 58% to $0.37 million for the quarter ended March 31, 2025, as compared to $0.88 million for the quarter ended March 31, 2024.

 

General and Administrative

 

   Three Months Ended
March 31,
   Changes 
   2025   2024   Amount   % 
   (In thousands, except percentages) 
General and administrative  $1,198   $1,181   $17    2%

 

General and administrative expenses increased by $0.02 million, or 2% to $1.2 million for the quarter ended March 31, 2025, as compared to $1.2 million for the quarter ended March 31, 2024.

 

Depreciation and amortization

 

    Three Months Ended
March 31,
    Changes  
    2025     2024     Amount     %  
    (In thousands, except percentages)  
Depreciation and amortization   $ 12     $ 536     $ (524 )     (98 )%

 

Depreciation and amortization expenses decreased by $0.52 million, or 98% to $0.01 million for the quarter ended March 31, 2025, as compared to $0.53 million for the quarter ended March 31, 2024.

 

Interest expense

 

    Three Months Ended
March 31,
    Changes  
    2025     2024     Amount     %  
    (In thousands, except percentages)  
Interest expense   $ 413     $ 149     $ 264       177 %

 

Interest expenses increased by $0.26 million, or 177% to $0.41 million for the quarter ended March 31, 2025, as compared to $0.14 million for the quarter ended March 31, 2024.

 

34

 

Revenue, Cost of Revenue and Operating Profit by Operating Segment

 

We manage and report our business under three operating segments which are Software services, Managed services and support and Platform services.

 

   Three Months Ended
March 31,
   Changes 
   2025   2024   Amount   % 
   (In thousands, except percentages) 
Software services  $1,734    2,025    (291)   (14)%
Managed services and Support   1,900    1,996    (96)   (5)%
Platform services   70    88    (18)   (20)%
Revenue  $3,704   $4,109   $(405)   (10)%

 

Revenue from Software services decrease by $0.3 million, or 14% to $1.73 million for the quarter ended March 31, 2025, as compared to $2.02 million for the quarter ended March 31, 2024. Revenue from Managed services and support decreased by $0.1 million, or 5% to $1.9 million for the quarter ended March 31, 2025, as compared to $1.99 million for the quarter ended March 31, 2024. Revenue from Platform Services decreased by $0.18 million, or 20% to $0.70 million for the quarter ended March 31, 2025, as compared to $0.88 million for the quarter ended March 31, 2024.

 

Factors affecting revenues of Software Services, Managed Services and Support and Platform Services

 

Our strategy is to achieve meaningful long-term revenue growth through sales of Managed Services and Support and Platform Services to existing and new clients within our target market. In order to increase our cross-selling opportunity between our operating segments and realize long time revenue growth, our focus has shifted more towards Managed Services and Support and Platform Services which is of recurring nature when compared to Software Services segment which is of non-recurring nature. This also helps in retaining existing customers by leveraging our Managed Services and Support and Platform Services as a growth agent. This renewed focus on driving demand for subscription and platform-based model will help us in expanding our customer base and enhance customer retention which is a challenge for our existing Software Services segment. Software Services contracts are driven by Time and Material and on-site employees delivering services at customers location.

 

Cost of Revenue

 

   Three Months Ended
March 31,
   Changes 
   2025   2024   Amount   % 
   (In thousands, except percentages) 
Software services  $1,543   $1,624   $(81)   (5)%
Managed services and support   1,823    1,415    408    29%
Platform services   9    56    (47)   (84)%
Cost of revenue  $3,375   $3,095   $280    9%

 

Cost of revenue from Software services decreased by $0.08 million, or 5% to $1.54 million for the quarter ended March 31, 2025, as compared to $1.62 million for the quarter ended March 31, 2024. Cost of revenue from Managed services and support increase by $0.40 million, or 29% to $1.82 million for the quarter ended March 31, 2025, as compared to $1.41 million for the quarter ended March 31, 2024. Cost of revenue from Platform services decreased by $0.04 million, or 85% to $0.01 million for the quarter ended March 31, 2025, as compared to $0.05 million for the quarter ended March 31, 2024.

 

35

 

Segment operating profits by reportable segment were as follows:

 

Operating profit by Operating Segment

 

 

Three months ended March 31, 2025
Particulars  Software
Services
   Managed
Services
   Platform
Services
   Total 
Revenue from customers   1,734    1,900    70    3,704 
Intersegment revenues   -    -    -    - 
Total   1,734    1,900    70    3,704 
Less:                    
Elimination of intersegment revenues   -    -    -    - 
Cost of revenue   (1,543)   (1,823)   (9)   (3,375)
Segmental gross profit   191    77    61    329 
Research and development   -    -    144    144 
Sales and marketing   175    191    7    373 
General and administrative   561    615    23    1,198 
Segmental loss   (544)   (729)   (113)   (1,386)
Interest expenses   (193)   (212)   (8)   (413)
Depreciation and amortization   -    -    (12)   (12)
Other income   52    57    2    111 
Income before income taxes   (685)   (884)   (131)   (1,700)
Income tax   -    -    -    - 
Income after income taxes   (685)   (884)   (131)   (1,700)

 

 

Three months ended March 31, 2024
Particulars  Software
Services
   Managed
Services
   Platform
Services
   Total 
Revenue from customers   2,025    1,996    88    4,109 
Intersegment revenues   -    -    -    - 
Total   2,025    1,996    88    4,109 
Less:                  - 
Elimination of intersegment revenues   -    -    -    - 
Cost of revenue   (1,625)   (1,414)   (56)   (3,095)
Segmental gross profit   400    582    32    1,014 
Research and development   -    -    127    127 
Sales and marketing   435    429    19    883 
General and administrative   582    574    25    1,181 
Segmental profit / (loss)   (617)   (421)   (139)   (1,177)
Interest expenses   (73)   (72)   (3)   (149)
Depreciation   -    -    (536)   (536)
Amortization   -    -    -    - 
Other income   -    -    -    - 
Income before income taxes   (691)   (493)   (678)   (1,862)
Income tax   -    -    -    - 
Income after income taxes   (691)   (493)   (678)   (1,862)

 

36

 

Liquidity and Capital Resources

 

Liquidity

 

The current ratio measures a company’s ability to pay off its current liabilities (payable within one year) with its total current assets such as cash, accounts receivable, and inventories. The higher the ratio, the better the company’s liquidity position. A good current ratio is between 1.2 to 2, which means that a business has 2 times more current assets than liabilities to covers its debts. The Company’s current ratio, based on the three months ended March 31, 2025 financial statement is 3 compared to 0.7 for the financial year ended December 31, 2024.

 

The Company’s current debt equity ratio, based on the three months ended March 31, 2025 financial statement is .37, compared to (1.38) for the quarter ended December 31, 2024.

 

The Company does not have inventory and hence the quick ratio is the same as current ratio.

 

Sources of Liquidity

 

As of March 31, 2025, our principal sources of liquidity consisted of cash and cash equivalents of $6.8 million. We believe that the future operating cash flows of the entity will provide adequate resources to fund ongoing cash requirements.

 

    As of
March 31,
2025
    As of
March 31, 2024
 
    (In thousands)  
Cash and cash equivalents   $ 6,826     $ 301  
Short-term investments            
Total cash, cash equivalents and short-term investments   $ 6,826     $ 301  

 

As of March 31, 2025, our principal sources of liquidity for working capital purposes were cash, cash equivalents and short-term investments totaling $6.8 million.

 

We have financed our operations primarily through financing activity and operating cash flows. We believe our existing cash, cash equivalents and short-term investments generated from operations will be sufficient to meet our working capital over the next 12 months. Our future capital requirements will depend on many factors including our growth rate, subscription renewal activity, the expansion of sales and marketing activities and the ongoing investments in platform development.

 

Cash Flows

 

The following table presents a summary of our consolidated cash flows provided by (used in) operating, investing, and financing activities for the periods indicated:

 

   As of
March 31, 2025
   As of
March 31, 2024
 
   (In thousands) 
Cash flows used in operating activities  $(5,557)  $(50)
Cash flows used in investing activities        
Cash flows provided by / (used in) financing activities   12,363    (883)
Net increase in cash and cash equivalents  $6,805   $(933)

 

37

 

Operating Activities

 

Net cash used in operating activities during the three months ended March 31, 2025, was $5.55 million compared to $0.05 million for the three months ended March 31, 2024.

 

Investing Activities

 

Net cash used in investing activities was $0 for the three months ended March 31, 2025, compared to $0 million for the three months ended March 31, 2024.

 

Financing Activities

 

Cash outflow/inflow from financing activities was $12.36 million for the three months ended March 31, 2025, compared to $(0.90) million for the three months ended March 31, 2024.

 

Off-Balance Sheet Arrangements

 

We do not have any relationships with unconsolidated organizations or financial partnerships, such as structured finance or special purpose entities that would have been established for the purpose of facilitating off-balance sheet arrangements or other contractually narrow or limited purposes as defined by Item 303(a)(4) of SEC Regulation S-K, as of March 31, 2025.

 

Item 3. Quantitative and Qualitative Disclosures about Market Risk.

 

We did not have investments and do not utilize derivative financial instruments to manage our interest rate risks.

 

Item 4. Controls and Procedures.

 

Evaluation of Disclosure Controls and Procedures and Changes in Internal Control over Financial Reporting

 

Disclosure controls and procedures (as defined in Rules 13a-15(e) and 15d-15(e)) are designed to ensure that information required to be disclosed by us in reports we file or submit under the Securities Exchange Act of 1934, as amended, is recorded, processed, summarized and reported within the appropriate time periods, and that such information is accumulated and communicated to the Chief Operating Officer and Chief Financial Officer, as appropriate, to allow timely discussions regarding required disclosure. We, under the supervision of and with the participation of our management, including our Chief Operating Officer and Chief Financial Officer, have evaluated the effectiveness of our disclosure controls and procedures. Based on that evaluation, our Chief Operating Officer and Chief Financial Officer concluded that the design and operation of our disclosure controls and procedures were effective as of March 31, 2025.

 

Changes in Internal Control over Financial Reporting 

 

There were no changes to our internal control over financial reporting during the three months ended March 31, 2025, that have materially affected, or are reasonable likely to materially effect, our internal controls over financial reporting.

 

38

 

PART II

 

OTHER INFORMATION

 

Item 1. Legal Proceedings.

 

From time to time, we are involved in routine litigation that arises in the ordinary course of business. We are not currently involved in any claims outside the ordinary course of business that are material to our financial condition or results of operations.

 

Item 1A. Risk Factors.

 

As of the date of this Quarterly Report on Form 10-Q, there have been no material changes to the risk factors disclosed in our Annual Report on Form 10-K , filed with the SEC on March 31, 2025. We may disclose changes to such factors or disclose additional factors from time to time in our future filings with the SEC.

 

Item 2. Unregistered Sales of Equity Securities and Use of Proceeds.

 

On February 27, 2025, we entered into Securities Purchase Agreements dated February 27, 2025 with institutional investors for the private placement of 36,190,485 units (each a, “Unit”), each Unit consisting of one share of the our common stock or one pre-funded warrant to purchase one share of common stock, one Series A Warrant (a “Series A Warrant”) to purchase one share of common stock and one Series B Warrant to purchase one share of common stock at an offering price of $0.42 per Unit (or $0.41999 per Unit in the case of Units that include pre-funded warrants).

 

Item 3. Defaults Upon Senior Securities.

 

Not applicable

 

Item 4. Mine Safety Disclosures.

 

Not applicable

 

Item 5. Other Information

 

None

 

39

 

Item 6. Exhibits

 

Exhibit No.   Description
3.1   Certificate of Incorporation of the Company (incorporated by reference to Exhibit 3.1 to the Company’s Registration Statement No. 333-259180, initially filed on August 30, 2021)
3.2   Bylaws of the Company (incorporated by reference to Exhibit 3.2 to the Company’s Registration Statement No. 333-259180, initially filed on August 30, 2021)
3.3   Amendment to Certificate of Incorporation of the Company (incorporated by reference to Exhibit 3.3 to the Company’s Registration Statement No. 333-259180, initially filed on August 30, 2021)
3.4   Series A Preferred Stock Certificate of Designation (incorporated by reference to Exhibit 3.4 to the Company’s Registration Statement No. 333-259180, initially filed on August 30, 2021)
3.5   Series A Preferred Stock Amended and Restated Certificate of Designations (incorporated by reference to Exhibit 3.5 to the Company’s Registration Statement No. 333-259180, initially filed on August 30, 2021)
4.1   Form of Series A Warrant (incorporated by reference to Exhibit 4.1 to the Company’s current report on Form 8-K, filed with the SEC on February 28, 2025)
4.2   Form of Series B Warrant (incorporated by reference to Exhibit 4.2 to the Company’s current report on Form 8-K, filed with the SEC on February 28, 2025)
4.3   Form of Pre-Funded Warrant (incorporated by reference to Exhibit 4.3 to the Company’s current report on Form 8-K, filed with the SEC on February 28, 2025)
10.1   Form of Securities Purchase Agreement (incorporated by reference to Exhibit 10.1 to the Company’s current report on Form 8-K, filed with the SEC on February 28, 2025)
10.2   Registration Rights Agreement (incorporated by reference to Exhibit 10.2 to the Company’s current report on Form 8-K, filed with the SEC on February 28, 2025)
10.3   Employment Agreement between Healthcare Triangle, Inc. and Ms. Sujatha Ramesh, dated March 18, 2025. (incorporated by reference to Exhibit 10.1 to the Company’s current report on Form 8-K, filed with the SEC on March 24, 2025)
10.4   Employment Agreement between Healthcare Triangle, Inc. and Mr. David Ayanoglou, dated April 10, 2025. incorporated by reference to Exhibit 10.1 to the Company’s current report on Form 8-K, filed with the SEC on April 11, 2025)
21.1   List of Subsidiaries of the Company (Incorporated by reference to the Company’s Annual Report on Form 10-K filed on March 8, 2022.)
31.1*   Certification of the Chief Operating Officer pursuant to Rule 13a-14(a) under the Securities Exchange Act of 1934, as adopted pursuant to Section 302 of the Sarbanes-Oxley Act of 2002
31.2*   Certification of the Chief Financial Officer pursuant to Rule 13a-14(a) under the Securities Exchange Act of 1934, as adopted pursuant to Section 302 of the Sarbanes-Oxley Act of 2002.
32.1+   Certification of the Chief Operating Officer pursuant to Section 13(a) or 15(d) of the Securities Exchange Act of 1934, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002.
32.2+   Certification of the Chief Financial Officer pursuant to Section 13(a) or 15(d) of the Securities Exchange Act of 1934, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002
101.INS   Inline XBRL Instance Document.
101.SCH   Inline XBRL Taxonomy Extension Schema Document.
101.CAL   Inline XBRL Taxonomy Extension Calculation Linkbase Document.
101.DEF   Inline XBRL Taxonomy Extension Definition Linkbase Document.
101.LAB   Inline XBRL Taxonomy Extension Label Linkbase Document.
101.PRE   Inline XBRL Taxonomy Extension Presentation Linkbase Document.
104   Cover Page Interactive Data File (formatted as Inline XBRL and contained in Exhibit 101).

 

* Filed herewith

 

+ Furnished herewith.

 

40

 

SIGNATURES

 

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned thereunto duly authorized.

 

  HEALTHCARE TRIANGLE, INC.
   
Date: May 20, 2025 /s/ Sujatha Ramesh
  Sujatha Ramesh
  Chief Operating Officer
  (Principal executive officer)
   
Date: May 20, 2025 /s/ David Ayanoglou
  David Ayanoglou
 

Chief Financial Officer

(Principal financial officer)

 

41

 

178 0.00 0001839285 false Q1 --12-31 0001839285 2025-01-01 2025-03-31 0001839285 2025-05-19 0001839285 2025-03-31 0001839285 2024-12-31 0001839285 us-gaap:SeriesAPreferredStockMember 2025-03-31 0001839285 us-gaap:SeriesAPreferredStockMember 2024-12-31 0001839285 2024-01-01 2024-03-31 0001839285 us-gaap:SeriesAPreferredStockMember us-gaap:PreferredStockMember 2024-12-31 0001839285 us-gaap:SeriesBPreferredStockMember us-gaap:PreferredStockMember 2024-12-31 0001839285 us-gaap:CommonStockMember 2024-12-31 0001839285 us-gaap:AdditionalPaidInCapitalMember 2024-12-31 0001839285 us-gaap:RetainedEarningsMember 2024-12-31 0001839285 us-gaap:RetainedEarningsMember 2025-01-01 2025-03-31 0001839285 us-gaap:SeriesAPreferredStockMember us-gaap:PreferredStockMember 2025-01-01 2025-03-31 0001839285 us-gaap:SeriesBPreferredStockMember us-gaap:PreferredStockMember 2025-01-01 2025-03-31 0001839285 us-gaap:CommonStockMember 2025-01-01 2025-03-31 0001839285 us-gaap:AdditionalPaidInCapitalMember 2025-01-01 2025-03-31 0001839285 us-gaap:SeriesAPreferredStockMember us-gaap:PreferredStockMember 2025-03-31 0001839285 us-gaap:SeriesBPreferredStockMember us-gaap:PreferredStockMember 2025-03-31 0001839285 us-gaap:CommonStockMember 2025-03-31 0001839285 us-gaap:AdditionalPaidInCapitalMember 2025-03-31 0001839285 us-gaap:RetainedEarningsMember 2025-03-31 0001839285 us-gaap:SeriesAPreferredStockMember us-gaap:PreferredStockMember 2023-12-31 0001839285 us-gaap:SeriesBPreferredStockMember us-gaap:PreferredStockMember 2023-12-31 0001839285 us-gaap:CommonStockMember 2023-12-31 0001839285 us-gaap:AdditionalPaidInCapitalMember 2023-12-31 0001839285 us-gaap:RetainedEarningsMember 2023-12-31 0001839285 2023-12-31 0001839285 us-gaap:RetainedEarningsMember 2024-01-01 2024-03-31 0001839285 us-gaap:SeriesAPreferredStockMember us-gaap:PreferredStockMember 2024-01-01 2024-03-31 0001839285 us-gaap:SeriesBPreferredStockMember us-gaap:PreferredStockMember 2024-01-01 2024-03-31 0001839285 us-gaap:CommonStockMember 2024-01-01 2024-03-31 0001839285 us-gaap:AdditionalPaidInCapitalMember 2024-01-01 2024-03-31 0001839285 us-gaap:SeriesAPreferredStockMember us-gaap:PreferredStockMember 2024-03-31 0001839285 us-gaap:SeriesBPreferredStockMember us-gaap:PreferredStockMember 2024-03-31 0001839285 us-gaap:CommonStockMember 2024-03-31 0001839285 us-gaap:AdditionalPaidInCapitalMember 2024-03-31 0001839285 us-gaap:RetainedEarningsMember 2024-03-31 0001839285 2024-03-31 0001839285 srt:MinimumMember 2025-03-31 0001839285 srt:MaximumMember 2025-03-31 0001839285 hcti:TwoThousandTwentyStockIncentivePlanMember 2025-03-31 0001839285 hcti:FiveCustomersMember us-gaap:SalesRevenueNetMember us-gaap:CustomerConcentrationRiskMember 2025-01-01 2025-03-31 0001839285 hcti:FiveCustomersMember us-gaap:SalesRevenueNetMember us-gaap:CustomerConcentrationRiskMember 2024-01-01 2024-03-31 0001839285 hcti:FiveCustomersMember us-gaap:AccountsReceivableMember us-gaap:CustomerConcentrationRiskMember 2025-01-01 2025-03-31 0001839285 hcti:FiveCustomersMember us-gaap:AccountsReceivableMember us-gaap:CustomerConcentrationRiskMember 2024-01-01 2024-12-31 0001839285 us-gaap:OperatingSegmentsMember hcti:SoftwareServiceMember 2025-01-01 2025-03-31 0001839285 us-gaap:OperatingSegmentsMember hcti:SoftwareServiceMember 2024-01-01 2024-03-31 0001839285 us-gaap:OperatingSegmentsMember hcti:SoftwareServiceMember 2024-01-01 2024-12-31 0001839285 us-gaap:OperatingSegmentsMember hcti:ManagedServicesAndSupportMember 2025-01-01 2025-03-31 0001839285 us-gaap:OperatingSegmentsMember hcti:ManagedServicesAndSupportMember 2024-01-01 2024-03-31 0001839285 us-gaap:OperatingSegmentsMember hcti:ManagedServicesAndSupportMember 2024-01-01 2024-12-31 0001839285 us-gaap:OperatingSegmentsMember hcti:PlatformServicesMember 2025-01-01 2025-03-31 0001839285 us-gaap:OperatingSegmentsMember hcti:PlatformServicesMember 2024-01-01 2024-03-31 0001839285 us-gaap:OperatingSegmentsMember hcti:PlatformServicesMember 2024-01-01 2024-12-31 0001839285 us-gaap:OperatingSegmentsMember 2025-01-01 2025-03-31 0001839285 us-gaap:OperatingSegmentsMember 2024-01-01 2024-03-31 0001839285 us-gaap:OperatingSegmentsMember 2024-01-01 2024-12-31 0001839285 us-gaap:OperatingSegmentsMember hcti:SoftwareServicesMember 2025-01-01 2025-03-31 0001839285 us-gaap:OperatingSegmentsMember hcti:ManagedServicesMember 2025-01-01 2025-03-31 0001839285 us-gaap:OperatingSegmentsMember hcti:SoftwareServicesMember 2024-01-01 2024-03-31 0001839285 us-gaap:OperatingSegmentsMember hcti:ManagedServicesMember 2024-01-01 2024-03-31 0001839285 hcti:Customer1Member us-gaap:SalesRevenueNetMember us-gaap:CustomerConcentrationRiskMember 2025-01-01 2025-03-31 0001839285 hcti:Customer2Member us-gaap:SalesRevenueNetMember us-gaap:CustomerConcentrationRiskMember 2025-01-01 2025-03-31 0001839285 hcti:Customer3Member us-gaap:SalesRevenueNetMember us-gaap:CustomerConcentrationRiskMember 2025-01-01 2025-03-31 0001839285 hcti:Customer4Member us-gaap:SalesRevenueNetMember us-gaap:CustomerConcentrationRiskMember 2025-01-01 2025-03-31 0001839285 hcti:Customer5Member us-gaap:SalesRevenueNetMember us-gaap:CustomerConcentrationRiskMember 2025-01-01 2025-03-31 0001839285 hcti:Customer1Member us-gaap:AccountsReceivableMember us-gaap:CustomerConcentrationRiskMember 2024-01-01 2024-03-31 0001839285 hcti:Customer2Member us-gaap:AccountsReceivableMember us-gaap:CustomerConcentrationRiskMember 2024-01-01 2024-03-31 0001839285 hcti:Customer3Member us-gaap:AccountsReceivableMember us-gaap:CustomerConcentrationRiskMember 2024-01-01 2024-03-31 0001839285 hcti:Customer4Member us-gaap:AccountsReceivableMember us-gaap:CustomerConcentrationRiskMember 2024-01-01 2024-03-31 0001839285 hcti:Customer5Member us-gaap:AccountsReceivableMember us-gaap:CustomerConcentrationRiskMember 2024-01-01 2024-03-31 0001839285 us-gaap:UnbilledRevenuesMember 2025-03-31 0001839285 us-gaap:UnbilledRevenuesMember 2024-12-31 0001839285 us-gaap:PrepaidExpensesAndOtherCurrentAssetsMember 2025-03-31 0001839285 us-gaap:PrepaidExpensesAndOtherCurrentAssetsMember 2024-12-31 0001839285 us-gaap:OtherCurrentAssetsMember 2025-03-31 0001839285 us-gaap:OtherCurrentAssetsMember 2024-12-31 0001839285 hcti:SeriesBConvertiblePreferredStockMember 2025-01-01 2025-03-31 0001839285 hcti:SeriesBConvertiblePreferredStockMember 2025-03-31 0001839285 hcti:SecurekloudTechnologiesIncMember 2025-01-01 2025-03-31 0001839285 hcti:SecurekloudTechnologiesIncMember 2024-01-01 2024-03-31 0001839285 2025-02-24 2025-02-24 0001839285 us-gaap:CommonStockMember 2025-02-24 0001839285 2025-02-24 0001839285 2025-02-27 0001839285 us-gaap:CommonStockMember hcti:PurchaseAgreementsMember 2025-02-27 0001839285 hcti:PrefundedWarrantsMember 2025-02-27 0001839285 hcti:SeriesAWarrantsMember 2025-02-27 0001839285 hcti:SeriesBWarrantMember 2025-02-27 0001839285 us-gaap:CommonStockMember 2025-02-27 0001839285 hcti:MrSureshVenkatachariMember us-gaap:SeriesAPreferredStockMember 2025-03-12 0001839285 hcti:SeriesBConvertiblePreferredStockMember 2024-10-21 0001839285 hcti:SeriesBConvertiblePreferredStockMember 2024-10-21 2024-10-21 0001839285 us-gaap:CommonStockMember 2025-03-31 0001839285 us-gaap:CommonStockMember 2025-01-01 2025-03-31 0001839285 hcti:PrefundedWarrantsMember 2025-03-31 0001839285 hcti:PrefundedWarrantsMember 2025-01-01 2025-03-31 0001839285 hcti:SeriesAWarrantsMember 2025-03-31 0001839285 hcti:SeriesBWarrantsMember 2025-03-31 0001839285 hcti:SeriesBWarrantsMember 2025-01-01 2025-03-31 0001839285 hcti:L1CapitalMember 2025-03-31 0001839285 hcti:PioneerGarageMember 2025-01-01 2025-03-31 0001839285 2023-12-28 0001839285 hcti:ConvertibleNotesMember 2023-12-28 0001839285 2023-12-28 2023-12-28 0001839285 hcti:CommonStockWarrantsMember 2023-12-28 2023-12-28 0001839285 hcti:CommonStockWarrantsMember 2023-12-28 0001839285 hcti:FirstTrancheNoteMember 2023-12-28 2023-12-28 0001839285 hcti:FirstTrancheWarrantsMember 2023-12-28 2023-12-28 0001839285 hcti:FirstTrancheWarrantsMember 2023-12-28 0001839285 hcti:SBFFacilityMember 2025-03-31 0001839285 hcti:SBFFacilityMember 2024-12-31 0001839285 hcti:SeacoastBusinessFundingMember 2025-03-31 0001839285 hcti:SeacoastBusinessFundingMember 2024-12-31 0001839285 hcti:OneSevenTwoZeroTwoFiveMember hcti:ConvertibleNotesMember 2025-01-01 2025-03-31 0001839285 hcti:OneSevenTwoZeroTwoFiveMember hcti:ConvertibleNotesMember 2025-03-31 0001839285 hcti:TwoThreeTwoZeroTwoFiveMember hcti:ConvertibleNotesMember 2025-01-01 2025-03-31 0001839285 hcti:TwoThreeTwoZeroTwoFiveMember hcti:ConvertibleNotesMember 2025-03-31 0001839285 hcti:TwoOneFourTwoZeroTwoFiveMember hcti:ConvertibleNotesMember 2025-01-01 2025-03-31 0001839285 hcti:TwoOneFourTwoZeroTwoFiveMember hcti:ConvertibleNotesMember 2025-03-31 0001839285 hcti:TwoOneEightTwoZeroTwoFiveMember hcti:ConvertibleNotesMember 2025-01-01 2025-03-31 0001839285 hcti:TwoOneEightTwoZeroTwoFiveMember hcti:ConvertibleNotesMember 2025-03-31 0001839285 hcti:TwoTwoOneTwoZeroTwoFiveMember hcti:ConvertibleNotesMember 2025-01-01 2025-03-31 0001839285 hcti:TwoTwoOneTwoZeroTwoFiveMember hcti:ConvertibleNotesMember 2025-03-31 0001839285 hcti:ConvertibleNotesMember 2025-01-01 2025-03-31 0001839285 hcti:CommonStockWarrantsMember 2024-12-31 0001839285 hcti:CommonStockWarrantsMember 2025-01-01 2025-03-31 0001839285 hcti:CommonStockWarrantsMember 2025-03-31 0001839285 hcti:CommonStockWarrantsMember 2023-12-31 0001839285 hcti:CommonStockWarrantsMember 2024-01-01 2024-03-31 0001839285 hcti:CommonStockWarrantsMember 2024-03-31 0001839285 hcti:UnvestedWarrantsMember 2024-12-31 0001839285 hcti:UnvestedWarrantsMember 2025-01-01 2025-03-31 0001839285 hcti:UnvestedWarrantsMember 2025-03-31 0001839285 hcti:UnvestedWarrantsMember 2023-12-31 0001839285 hcti:UnvestedWarrantsMember 2024-01-01 2024-03-31 0001839285 hcti:UnvestedWarrantsMember 2024-03-31 0001839285 hcti:SeacoastBusinessFundingMember 2025-03-31 0001839285 hcti:SeacoastBusinessFundingMember 2024-12-31 0001839285 us-gaap:ConvertibleDebtMember 2025-03-31 0001839285 us-gaap:ConvertibleDebtMember 2024-12-31 0001839285 hcti:PayrollMember 2025-03-31 0001839285 hcti:PayrollMember 2024-12-31 0001839285 hcti:AuditFeesMember 2025-03-31 0001839285 hcti:AuditFeesMember 2024-12-31 0001839285 hcti:InsuranceMember 2025-03-31 0001839285 hcti:InsuranceMember 2024-12-31 0001839285 us-gaap:OtherCurrentLiabilitiesMember 2025-03-31 0001839285 us-gaap:OtherCurrentLiabilitiesMember 2024-12-31 0001839285 us-gaap:StockOptionMember 2025-01-01 2025-03-31 0001839285 us-gaap:StockOptionMember 2024-01-01 2024-03-31 0001839285 us-gaap:StockOptionMember 2024-12-31 0001839285 hcti:EmployeeShareOptionPlanMember 2024-12-31 0001839285 hcti:EmployeeShareOptionPlanMember 2025-01-01 2025-03-31 0001839285 us-gaap:StockOptionMember 2025-03-31 0001839285 hcti:EmployeeShareOptionPlanMember 2025-03-31 0001839285 us-gaap:StockOptionMember 2023-12-31 0001839285 hcti:EmployeeShareOptionPlanMember 2023-12-31 0001839285 hcti:EmployeeShareOptionPlanMember 2024-01-01 2024-03-31 0001839285 us-gaap:StockOptionMember 2024-03-31 0001839285 hcti:EmployeeShareOptionPlanMember 2024-03-31 0001839285 srt:MinimumMember 2024-01-01 2024-12-31 0001839285 srt:MaximumMember 2024-01-01 2024-12-31 0001839285 srt:MinimumMember 2023-01-01 2023-12-31 0001839285 srt:MaximumMember 2023-01-01 2023-12-31 0001839285 2024-01-01 2024-12-31 0001839285 2023-01-01 2023-12-31 0001839285 hcti:SeriesBWarrantsMember 2025-01-01 2025-03-31 xbrli:shares iso4217:USD iso4217:USD xbrli:shares xbrli:pure

ATTACHMENTS / EXHIBITS

ATTACHMENTS / EXHIBITS

CERTIFICATION

CERTIFICATION

CERTIFICATION

CERTIFICATION

XBRL SCHEMA FILE

XBRL CALCULATION FILE

XBRL DEFINITION FILE

XBRL LABEL FILE

XBRL PRESENTATION FILE

IDEA: R1.htm

IDEA: R2.htm

IDEA: R3.htm

IDEA: R4.htm

IDEA: R5.htm

IDEA: R6.htm

IDEA: R7.htm

IDEA: R8.htm

IDEA: R9.htm

IDEA: R10.htm

IDEA: R11.htm

IDEA: R12.htm

IDEA: R13.htm

IDEA: R14.htm

IDEA: R15.htm

IDEA: R16.htm

IDEA: R17.htm

IDEA: R18.htm

IDEA: R19.htm

IDEA: R20.htm

IDEA: R21.htm

IDEA: R22.htm

IDEA: R23.htm

IDEA: R24.htm

IDEA: R25.htm

IDEA: R26.htm

IDEA: R27.htm

IDEA: R28.htm

IDEA: R29.htm

IDEA: R30.htm

IDEA: R31.htm

IDEA: R32.htm

IDEA: R33.htm

IDEA: R34.htm

IDEA: R35.htm

IDEA: R36.htm

IDEA: R37.htm

IDEA: R38.htm

IDEA: R39.htm

IDEA: R40.htm

IDEA: R41.htm

IDEA: R42.htm

IDEA: R43.htm

IDEA: R44.htm

IDEA: R45.htm

IDEA: R46.htm

IDEA: R47.htm

IDEA: R48.htm

IDEA: R49.htm

IDEA: R50.htm

IDEA: R51.htm

IDEA: R52.htm

IDEA: R53.htm

IDEA: R54.htm

IDEA: R55.htm

IDEA: R56.htm

IDEA: R57.htm

IDEA: R58.htm

IDEA: R59.htm

IDEA: R60.htm

IDEA: R61.htm

IDEA: FilingSummary.xml

IDEA: MetaLinks.json

IDEA: ea0241579-10q_health_htm.xml